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Abstract 
 
Targeted molecular imaging is an emerging non-invasive tool for the identification and 
characterisation of cancers based on physiological and molecular properties. Molecular 
imaging is likely to play a significant role in the development and validation of future 
biomarkers due to the ability to identify and monitor real time tumour characteristics non-
invasively. There is currently a need to identify novel biomarkers that can be used to 
target, or inform on, tumour specific processes. 
 
The human anthrax toxin receptors Tumour Endothelial Marker 8 (TEM8) and Capillary 
Morphogenesis Gene 2 (CMG2) have been identified as potential novel tumour 
biomarkers. TEM8 and CMG2 are cell surface receptors involved in angiogenesis and 
extracellular matrix homeostasis, processes that are important for tumour growth and 
metastasis. TEM8 is particularly interesting due to its tumour specific upregulation and 
undetectable expression in many healthy adult tissues. One method to target these 
receptors is to exploit their exogenous ligand Protective Antigen (PA). PA is a protein 
produced by the bacterium B. anthracis that mediates binding and internalisation of toxins 
into cells. Whilst preclinical studies have shown that PA can be used to specifically target 
toxins to tumours, the tumour specific localisation of PA in vivo has yet to be 
demonstrated.  
 
We have expressed recombinant PA, using an E. coli expression system, and purified the 
protein by liquid chromatography techniques. PA was non-specifically labelled with an 
amine reactive near infra-red fluorescent dye for optical imaging or 89Zr-Desferoxamine 
(89Zr-DFO) for positron emission tomography (PET). The labelled PA was intravenously 
(IV) injected into female HPV38E6E7-FVB mice, a transgenic mouse model of squamous 
cell carcinoma (SCC) that endogenously produces tumours in response to repeated UV 
irradiation. 
 
The fluorescently labelled PA protein was highly specific to the SCC tumours, resulting in 
rapid tumour uptake and exclusive tumour identification 24 hours post injection. Post 
mortem analysis, 48 hours post injection, showed that the fluorescence in the tumour was 
significantly higher (p < 0.002, two tailed paired T test) than the adjacent skin, the liver, 
and the kidneys. Immunofluorescence analysis of formalin-fixed paraffin-embedded skin 
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tissues identified for the first time that both TEM8 and CMG2 are upregulated in SCC 
tumours compared to healthy skin, with the administered PA protein more significantly 
colocalised with TEM8 expression than CMG2 expression. As TEM8 and CMG2 appear to 
be expressed within different structures of the skin, the greater localisation of PA to TEM8 
expression may be due to improved accessibility from an i.v. administered agent.  
 
PET imaging of 89Zr radiolabelled PA also showed tumour uptake, reaching a maximum 
approximately 5 hours post injection. However, the tumour uptake was relatively low with 
the majority of activity present in the kidneys. Analysis of biodistribution revealed that PA 
was rapidly cleared from the blood through hepatic and renal clearance mechanisms, with 
significant radioactivity retained within the kidneys. Rapid clearance can be an 
advantageous attribute for a targeted imaging agent, allowing rapid assessment after 
administration. However, the non-specific uptake of radioactivity as the result of PA 
degradation is a limitation of the 89Zr-DFO labelling. Further development is needed to 
improve PA as a PET imaging agent, utilising other radionuclides or protein modifications. 
 
Due to its high specificity for receptors overexpressed on many tumours and its natural 
internalisation function, PA has the potential to be used for diagnostic and therapeutic 
targeting of cancers. Our results demonstrate upregulation of both anthrax toxin receptors 
on SCC tumours, with TEM8 exhibiting great accessibility from an i.v. administered PA 
imaging agent. PA has the potential to be developed as a systemic targeting agent of 
SCC. Further work is needed to assess the in vivo expression of the anthrax toxin 
receptors during tumour development, in order to characterise their role in tumourigenesis. 
The HPV38E6E7-FVB mouse model is ideal for longitudinal studies biomarker 
assessment, developing tumours in an environment that is physiologically relevant and 
clinically translatable. Future work would benefit from characterization of how different 
labelling techniques and imaging molecules affect the biodistribution of PA in vivo. 
Additionally, a rationally designed molecule based on PA with improved biological 
properties could be developed for future cancer diagnostic and therapeutic applications.  
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Chapter 1 – Anthrax Toxin Receptors: Tumour Biomarkers for Molecular Imaging 
 
1.1 Literature Review 
 
1.1.1 Introduction 
 
Molecular imaging is a powerful non-invasive tool that can be used for the identification 
and prognostic assessment of cancers, as well as the monitoring of therapeutic delivery 
and effect, based on physiological and molecular characteristics (1). There are various 
molecular imaging techniques used for the detection and assessment of tumours, each 
possessing particular advantages and disadvantages in spatiotemporal resolution, 
sensitivity, and cost (2). Contrast enhanced imaging is of particular interest in oncology, 
but there is a need to develop new agents that target specific tumour characteristics to 
improve detection and treatment options (3). Identification of biomarkers that are shared 
by many tumours, with applications in targeting developing tumours, is of particular 
interest. There are several key aspects important for molecular imaging biomarkers; 
differential expression in healthy and diseased tissue, sufficient expression for detection, 
accessible to an administered agent, and preferably able to internalise (4). Potential 
biomarkers are often associated with tightly controlled processes, such as extracellular 
matrix (ECM) homeostasis and angiogenesis, which are required for tumour development 
and progression. 
 
ECM homeostasis or remodelling is a highly dynamic and important process affecting 
many cellular and tissue functions (5). The ECM functions to not only provide structural 
support for individual cells and organs, but also regulates cellular functions including 
proliferation, differentiation, organisation, and biochemical signalling through receptor 
interactions (5). It has been suggested that the ECM regulates many of the cellular 
responses that are characterised as the hallmarks of cancer (6). The ECM of tumours is 
generally stiffer than healthy tissue, which stimulates cellular proliferation and 
immortalisation through biophysical and biochemical processes (6). This increased 
stiffness also correlates with increased invasiveness and metastatic potential of tumours 
(6). Biomarkers that can be used to inform on the pathological changes to ECM regulation 
have applications in tumour detection, prognosis, and therapeutic monitoring.  
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The ECM also plays an essential role in cell-cell interactions mediating process such as 
angiogenesis through signal exchange between tumour cells and endothelial cells (7). 
Angiogenesis is a critical process in normal physiology and some diseases. It is 
characterised by the formation of new blood vessels from the pre-existing vasculature. The 
regulation of angiogenesis is a complex system involving both activator and inhibitor 
molecules that are expressed at varying levels in response to environmental changes. As 
tumour growth and metastasis is reliant on angiogenesis and angiogenic factors (8), 
targeting these molecules is of particular interest in cancer research. While there is 
promise in anti-angiogenic therapies for the treatment of cancer (9), targeting these 
receptors may have side effects due to their important functions in healthy tissues (10). 
Accordingly, this has driven research into the discovery and characterisation of biomarkers 
that can be used to non-invasively identify and monitor tumour specific angiogenic 
processes in vivo. It is important to identify and treat tumours at the earliest stage possible, 
and targeting early tumour indicators is therefore essential. Since dysregulation of ECM 
homeostasis and activation of angiogenesis are both essential for tumour growth beyond 
2-3 mm in diameter (11), targeting receptors that inform on these processes would be of 
significant benefit. Whilst it is possible to monitor structural changes to the tumour 
environment (12) or develop imaging agents against the most common angiogenic 
receptors (13), identifying a biomarker that can link tumour specific ECM changes with 
angiogenesis would have a significant impact.  
 
Potential biomarkers of both ECM homeostasis and angiogenesis are the cell surface 
receptors known as anthrax toxin receptors, Tumour Endothelial Marker 8 (TEM8) and 
Capillary Morphogenesis Gene 2 (CMG2). TEM8 and CMG2 are highly conserved integrin-
like transmembrane proteins consisting of extracellular von Willebrand factor type A (VWA) 
(14) and immunoglobulin-like (Ig-like) domains, a single-pass transmembrane domain, and 
a cytoplasmic domain (15) (Fig. 1-1A) The conserved VWA domain is comprised of five 
parallel β-strands and one shorter antiparallel β-strand forming a central β-sheet 
surrounded by six amphipathic α-helices (16) (Fig. 1-1B). Within the VWA domain resides 
a conserved Mg2+ coordination site known as a metal ion dependent adhesion site 
(MIDAS) involved in ligand binding (16,17) (Fig. 1-1B-C). VWA domains are commonly 
involved in extracellular functions including cell adhesion, and extracellular matrix 
interactions (18). However, a small number of VWA domains are also known to be 
involved in intracellular processes such as transcription, DNA repair, and transport (18).  
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Figure 1-1. The anthrax toxin receptors share a conserved domain structure.  
TEM8 and CMG2 proteins consist of extracellular von Willebrand factor type A (VWA) and 
immunoglobulin like (Ig-like) domains, a single pass transmembrane region (TM), and 
cytoplasmic tail domains (A). The VWA domains contain a conserved disulfide bond 
between the N and C terminal regions. Black arrows represent cytoplasmic cysteine 
palmitoylation sites; TEM8 (C346, C347, C481, C521); CMG2 (C344, C345, C478, C482). 
White arrows represent tyrosine phosphorylation sites; TEM8 (Y382, Y383, Y425, Y447, 
Y465, Y195, Y501, Y512); CMG2 (Y380, Y381, Y445, Y463). X-ray crystallography 
structures of TEM8 (green; PDB 3N2N) and CMG2 (grey; PDB 1T6B) VWA domains 
aligned using PyMOL molecular viewer (B). The overlayed structures demonstrate high 
structural similarity. Top view of aligned TEM8 and CMG2 structures (C). The conserved 
metal ion dependent adhesion site (MIDAS) residue sidechains are displayed (serine, 
blue; aspartate, cyan; threonine, magenta). The conserved aspartate is residue 150 in 
TEM8 and 148 in CMG2. The metal ion is represented by a yellow sphere. 
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Whilst these receptors were subsequently identified to be the targets of the anthrax toxins 
produced by Bacillus anthracis (19), their discovery was the result of screening gene 
expression during angiogenesis. TEM8 was discovered by global gene expression 
analysis during an attempt to systematically identify potential markers of the tumour 
endothelium associated with colorectal cancer (20). TEM8 was one of nine TEMs chosen 
based on their prominent expression on tumour endothelial cells with low or undetectable 
expression on normal healthy endothelial cells (20). Further investigation highlighted 
TEM8 as a potential marker of tumour specific angiogenesis due to undetectable 
expression in the developing corpus luteum (20), a regenerative structure in the ovaries 
that undergoes intense angiogenesis (8). CMG2 was discovered when screening 
differential gene expression during human capillary tube formation (21). It was also 
observed to bind collagen type IV and laminin, targeting the ligands to the endoplasmic 
reticulum, thereby suggesting a role in basement extracellular matrix synthesis and 
assembly (21). The anthrax toxin receptors have been identified to be potential tumour 
biomarkers based on their mRNA or protein expression, but they may have a greater 
potential as imaging biomarkers. Anthrax toxin receptors possess the key aspects of a 
molecular imaging biomarker. They are associated with key processes in tumour 
development, located at the surface of endothelial cells accessible via the blood, and are 
able to actively internalise bound ligands. Targeted molecular imaging of the anthrax toxin 
receptor could provide valuable information on tumour specific ECM homeostasis and 
angiogenesis, non-invasively, with physiological relevance, in real time. TEM8 and CMG2 
are highly orthologous. With 96% and 84% amino acid identity between human and mouse 
proteins respectively, they are a viable target for translational research. Such high degree 
of conservation suggests that these receptors have highly important and specific functions 
with potential similarities that could be used to identify specific tumours. 
 
1.1.2 Anthrax Toxin Receptors are Cancer Biomarkers 
 
The anthrax toxin receptors have been identified to be associated with cancer in clinical 
samples of multiple tumours. TEM8 is significantly overexpressed in patient derived tissue 
samples of colorectal (22), gallbladder (23), lung (24), and triple negative breast (25-27) 
cancers compared to low or undetectable expression in healthy controls. The expression 
level of TEM8 in colorectal or gallbladder cancer increases with grade and clinical staging 
(22,23), and is associated with shorter survival outcomes in breast cancer (26). The 
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increase in expression of TEM8 observed at later, more invasive stages of cancers could 
be a mechanism of ECM dysregulation to promote invasion into healthy tissues. 
CMG2 has been suggested to be an oncogene of glioma, increasing in expression with 
clinical grade (28). Conversely, CMG2 is inversely correlated to progression and survival in 
breast cancer (29) and soft tissue sarcoma (30). The function of CMG2 in tumour 
development appears to be more complex than TEM8, the decreased expression 
observed in breast cancer may be a factor in its invasiveness and metastatic potential 
while overexpression in glioma may promote angiogenesis.   
 
Each of the anthrax toxin receptors are potential biomarkers individually, combined they 
may have greater potential. Unfortunately, despite being highly conserved, the anthrax 
toxin receptors are rarely studied together. It is unknown if the expression of both TEM8 
and CMG2 are important factors in tumour development. Currently, the naturally low 
expression of TEM8 in healthy adult tissues and upregulation in many tumours makes it a 
particularly attractive target, consequently it has been more widely studied with respect to 
cancer than CMG2. This differential expression of TEM8 also makes it a promising target 
for molecular imaging. Although the function of the anthrax toxin receptors is not 
completely understood, their apparent involvement in tumour specific development is 
encouraging as cancer biomarkers. 
 
1.1.3 Anthrax Toxin Receptors Regulate Extracellular Matrix Homeostasis 
 
In humans, loss of TEM8 and CMG2 function result in rare conditions that are 
characterised by disruption of ECM homeostasis, known as GAPO (growth retardation, 
alopecia, pseudoanodontia, and progressive optic atrophy) syndrome (31) and hyaline 
fibromatosis syndrome (32) respectively. The human pathology of TEM8 and CMG2 
disruption can be emulated in mouse models, due to extremely high protein conservation. 
Genetic disruption of TEM8 results in viable mice that showed progressive growth 
retardation and bone loss (33), as well as misaligned incisors (34), similar to GAPO 
syndrome symptoms. Histological analysis of these mice revealed a general excess of 
ECM with focal deposits of collagen types I and VI in the ovaries and uterus (33). Genetic 
knockdown of CMG2 similarly results in accumulation of collagen VI by disrupting ligand 
induced lysosomal degradation (32). These results demonstrate that the anthrax toxin 
receptors primarily function in ECM homeostasis during development, facilitating the 
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cellular internalisation and degradation of specific collagen subtypes as well as related 
signalling processes. The anthrax toxin receptors also function to regulate matrix 
metalloproteinase 2 (MMP2) via membrane type 1 matrix metalloproteinase (MTP1 MMP) 
dependent activation (33,35). MMP2 is enzyme associated with cancer invasion that 
cleaves gelatin and several collagen subtypes (36,37). The regulation of the ECM is highly 
important in the development and progression of cancers (38). If the expression of the 
anthrax toxin receptors can inform on pathological changes to the ECM in vivo, they could 
prove to be valuable molecular targets for diagnostic, prognostic, and therapeutic 
purposes.  
 
Mice that are genetically deficient in TEM8 show impaired xenograft tumour growth 
compared to wild type mice (39), demonstrating that host expression of TEM8 is 
necessary for optimal tumour growth. Interestingly, host expression of TEM8 alone is not 
sufficient for tumour growth. Targeted knockdown of TEM8 expression in cancer cell lines 
by shRNAs was also shown to reduce the growth and proliferation of osteosarcoma (40) 
and breast cancer (41) in vivo. Although these results demonstrate that tumour growth is 
not dependent on TEM8 expression, it appears that optimal growth of xenograft tumours 
requires TEM8 to be present in both the cancer cells and the surrounding healthy tissue. 
This suggests that the role TEM8 plays in tumour development involves remodelling or 
crosstalk between tumour and healthy tissue which is necessary for expansive growth or 
invasion into surrounding tissues. The cellular fate of the anthrax toxin receptors (Fig. 1-2) 
further demonstrate their potential role in ECM homeostasis. TEM8 undergoes regular 
endosomal recycling (42) indicating a potential regulatory mechanism through intracellular 
receptor sequestration, a process that is likely to be shared by CMG2. An equilibrium 
occurs between cell surface exposed and intracellular anthrax toxin receptors (32,42). The 
availability of surface exposed receptors is dependent on environmental conditions, similar 
to the mechanism of epidermal growth factor receptor (EGFR) regulation (32). This is 
evident in vitro where cells express more TEM8 when grown on collagen compared to 
gelatin (43). TEM8 and CMG2 also undergo ligand activated lipid raft clustering (44) and 
internalisation (45). After ligand binding, the receptor is depalmitoylated allowing 
redistribution and clustering in lipid rafts (44). The depalmitoylation and receptor clustering 
is likely to facilitate the subsequent tyrosine phosphorylation by Src-like kinases and 
ubiquitination by E3 ligase Cbl, triggering clathrin mediated endocytosis (45).  
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Figure 1-2. Illustration of the cellular fate of the anthrax toxin receptors.  
Unbound receptors undergo slow endosomal recycling, regulating cellular location and 
receptor degradation. An equilibrium exists between receptors located in the recycling 
pathway and at the cell surface. Upon ligand binding the anthrax toxin receptors are 
depalmitoylated, allowing the receptors to cluster in lipid rafts. Removal of palmitate allows 
src-like kinases to phosphorylate cytoplasmic domain tyrosine residues. The combination 
of lipid raft clustering and tyrosine phosphorylation leads to signal amplification and 
activation of anthrax toxin receptor signalling pathways. Phosphorylation of the receptors 
also leads to ubiquitination and subsequent internalization via clathrin coated pits. Upon 
internalization the receptor dissociates from its ligand in either the early or late endosome, 
depending on the binding affinity. The receptor is then either processed into the recycling 
pathway for return to the cell surface or degraded.  
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Phosphorylation of transmembrane receptors by non-receptor tyrosine kinases regulates 
many cellular functions, transducing signals in response to extracellular cues (46). 
Although the specific signalling pathways of the anthrax toxin receptors are unknown, the 
tyrosine phosphorylation is likely to be important in regulating cellular processes 
associated with ECM homeostasis. A splice variant caused by a frameshift mutation within 
the C-terminal region of TEM8, removing the tyrosine phosphorylation sites, has been 
identified to be a cause of GAPO syndrome (31). Targeting these receptors may provide 
valuable information on the disruption of the ECM caused by cancers. TEM8 in particular 
may provide the means to target and monitor the tumour ECM related to angiogenesis due 
to selective upregulation on the tumour endothelium. 
 
1.1.4 Tumour Endothelial Marker 8 is a Marker of Tumour Angiogenesis 
 
TEM8 has been of particular interest as a tumour biomarker due to its overexpression 
during tumour angiogenesis. Inhibition of TEM8 results in a reduction or inhibition of 
angiogenesis in a variety of tumour models (39,47,48). Importantly, unlike other receptors 
involved in angiogenesis, TEM8 inhibition does not affect other adult angiogenic events 
such as wound healing (34,39) and liver regeneration (39). The tumour specific expression 
and function of TEM8 makes it a potential target for identifying tumour angiogenesis. 
Competitive inhibition of the c-Met receptor by NK4, a truncated Hepatocyte Growth 
Factor/Scatter Factor (HGF/SF) molecule that binds to the receptor without activating 
signal transduction, resulted in decreased TEM8 expression in a prostate cancer xenograft 
model (49). c-Met is a tightly controlled receptor involved in numerous cellular signalling 
pathways including cell proliferation, motility, and tissue homeostasis (50). Inhibition of the 
c-Met signalling affecting the expression of TEM8 is an interesting result that suggests a 
connection between TEM8 and angiogenic processes. 
 
It was discovered that TEM8 forms a multi-protein complex with vascular endothelial 
growth factor receptor 2 (VEGFR2) and β1 integrin (51). Missense mutations in TEM8 that 
disrupt this complex cause infantile haemangioma (52), a common benign tumour of 
infancy characterised by localised regions of disordered angiogenesis (53). The disruption 
of this complex results in the suppression of nuclear factor of activated T-cells (NFAT) 
dependent vascular endothelial growth factor receptor 1 (VEGFR1) expression, 
consequently increasing VEGF-dependent VEGFR2 activation (51). Similarly, TEM8 
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knockout mice also exhibit decreased VEGFR1 and β1 integrin expression, increased 
VEGF expression and VEGFR2 signalling (33). It is possible that there is a connection 
between the relative expression of VEGFR1 and VEGFR2 that may control or be 
controlled by TEM8 expression. When TEM8 expression is low, VEGFR1 expression is 
low while VEGFR2 is high. When TEM8 is overexpressed the VEGFR1/2 expression is 
reversed. This switch in expression of VEGFR1/2 promotes tumour angiogenesis (54) and 
correlates to the expression of TEM8 (20). It is possible that the TEM8 expression is the 
result of upregulation of abnormal angiogenic processes and functions to regulate the 
ECM allowing expansive tumour growth, invasion into healthy tissue, and metastasis.  
An alternate theory based on observations that TEM8 expression increases in cells 
starved of growth factors (39), suggests that local decreases in growth factor availability, 
caused by erratic blood flow and increased competition through overexpression of growth 
factor receptors, may drive the expression of TEM8 resulting in an increase of pathogenic 
angiogenesis as part of a survival pathway (39). However, it is unclear whether in vitro 
characteristics of TEM8 expression and function translate in vivo. Immunoprecipitation and 
Western blots performed on a diverse variety of human cancer cell lines grown in vitro and 
in vivo show markedly different expression of TEM8 (55). This significant change in 
expression is likely due to the different cellular environments in vitro and in vivo, especially 
regarding growth factors and ECM components. To identify if TEM8 is a potentially 
relevant biomarker of tumour specific angiogenesis, in vivo studies are needed to 
understand the expression changes in response to tumour development over time and in 
response to antiangiogenic treatments. Due to the complicated nature of processes such 
as ECM homeostasis and angiogenesis it is important to understand how these receptors 
respond in a physiologically relevant environment. Targeted molecular imaging is uniquely 
suited to assessing potential biomarkers non-invasively, in real time, and within a 
physiological environment. If TEM8 expression informs on the angiogenic potential of 
cancers it would have significant impact as a diagnostic and prognostic biomarker, in 
addition to a potential drug target. 
 
1.1.5 Molecular Imaging of Tumour Endothelial Marker 8 
 
The development of a molecular imaging agent targeting the anthrax toxin receptors has 
significant potential to translate into a clinically useful agent. While the majority of in vivo 
studies focus on therapeutic applications of targeting the anthrax toxin receptors, there is 
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limited knowledge about the biodistribution of these agents. Imaging techniques can be 
used to validate the tumour specific localisation of targeted agents non-invasively, and 
provide important information about non-specific tissue uptake, clearance and 
degradation.  
 
A fluorescently labelled anti-TEM8 antibody, administered to mice bearing human 
colorectal adenocarcinoma xenografts, was identified to specifically localised to the tumour 
vasculature but was not detected in the vasculature of the brain, heart, intestine, liver, 
muscle, spleen, or stomach (39). The localisation to the tumour vasculature raises the 
question whether the expression of TEM8 is endothelial cell specific in vivo, in spite of 
generalised expression in cancer cell lines, or whether the antibody suffers from poor 
tissue penetration. The same antibody was further utilised to develop a 89Zr 
desferrioxamine conjugated Positron Emission Tomography (PET) imaging agent (55).  
 
Biodistribution of the antibody resulted in the highest radioactivity in the spleen and liver, 
decreasing with time, followed by the femur increasing with time. The uptake in spleen and 
liver suggest rapid clearance of the antibody from the blood, with antibody degradation 
leading to free 89Zr uptake in the bone. The radiolabelled antibody exhibited tumour uptake 
that correlated with vessel density in multiple xenograft models (55). The correlation 
between anti-TEM8 uptake and tumour vessel density is further evidence of TEM8 playing 
a role in tumour angiogenesis. The tumour uptake of radioactivity reached its maximum 1 
day post injection, which was retained for two days before rapidly decreasing (55). The 
tumour clearance was suggested to be a result of metabolism and chelate instability after 
internalisation, allowing free 89Zr to clear from the tumour resulting in bone uptake (55). 
However, 89Zr is generally described to remain within cells once internalised (56,57), an 
advantageous property that allows continual uptake of radioactivity over time for maximum 
contrast. Whilst this study shows promise for a TEM8 targeting antibody for multiple 
cancers, the major disadvantage of this antibody as an imaging agent is its rapid 
clearance. It is likely that the poor performance observed is a result of the nu/nu athymic 
nude mouse model used. The anti-TEM8 antibody is a human mouse chimeric monoclonal 
antibody consisting of human variable domains and mouse IgG2a constant domains. In 
the nu/nu athymic nude model mouse IgG2a is known to be rapidly eliminated from the 
blood, primarily through the spleen and liver, due to low endogenous IgG2a (58,59). As 
this is a very specific phenomenon, it is likely that in a different mouse model or different 
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IgG subtype would greatly improve circulation and tumour uptake of the anti-TEM8 
antibody. 
 
Antibodies suffer from several limitations with respect to production costs, poor tissue 
penetration, and complex or difficult to predict modes of action (60).Whilst antibodies are 
effective therapeutic and diagnostic tools, non-antibody engineered proteins are a potential 
alternative. Similar to antibodies, recombinant proteins can have high selectivity and 
potency, but have advantages with more predictable modes of action, significantly reduced 
production costs, and greater potential for rational design to improve function. Unlike other 
cancer biomarkers, the anthrax toxin receptors can be specifically targeted by a highly 
selective exogenous ligand. The advantage of using a known ligand as a targeting agent 
over antibodies is the ability to trigger receptor clustering and internalisation, amplifying the 
uptake of a diagnostic or therapeutic agent into cells that overexpress the anthrax toxin 
receptors.   
 
1.1.6 Protective Antigen Targets Tumours 
 
Protective Antigen (PA) is a protein produced by B. anthracis that mediates the binding 
and translocation of the anthrax toxin effector components into cells. PA is expressed as 
an 83 kDa protein that binds to the anthrax toxin receptors primarily through interaction 
between a loop in domain IV and the receptors’ MIDAS (61), and a secondary interaction 
with domain II (62) (Fig. 1-3A-B). The 83 kDa PA protein is cleaved by a furin protease to 
produce a 63 kDa protein that oligomerises into a heptameric ring structure (63), generally 
referred to as the pre-pore. The toxin effector molecules edema factor (EF) and lethal 
factor (LF), enzymes responsible for the pathogenesis of anthrax, are able to bind to the 
exposed hydrophobic surface of the pre-pore through interactions with three sites across 
two PA molecules (64). The complex undergoes cell mediated endocytosis (65) where the 
acidic environment activates receptor dissociation (66), PA pore formation and unfolding of 
EF and LF for translocation (67). The low pH of the endosome creates an unstable 
environment within the protein complex that can be relieved through a conformational 
change. This results in the formation of a large beta barrel spanning the endosomal 
membrane (63,68,69). The ion channel like pore (Fig. 1-3C) allows for translocation of the 
unfolded α-helical configuration of LF and EF into the cytosol (67,69).  
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Due to higher affinity and expression in healthy tissues, CMG2 is considered to be the 
major receptor responsible for anthrax pathogenesis (70). However, as toxicity is 
dependent on cellular expression of the anthrax toxin receptors (71), selective 
Figure 1-3. Key aspects of PA-receptor interactions and pore formation.X-ray 
crystallography structure of 83 kDa PA (PDB 1T6B), consisting of four domains (D I-IV, 
each coloured a different shade of blue) (A). Highlighted loops from domains II (red) and 
IV (pink) directly interact with the VWA domain. PA binds the anthrax toxin receptors 
through interaction with two conserved regions (B). Domain II of PA interacts with a 
conserved pocket between alpha helixes α3 and α4. Domain IV interacts with the receptor 
MIDAS region, direct contact occurs between the metal ion and PA aspartate 683. CryoEM 
structure of the PA heptameric pore complex (PDB 3J9C) (C). The low pH of the 
endosome results in unfolding of PA domain II, forming an ion channel like beta barrel that 
spans the endosomal membrane. PA domain IV is missing from the pore structure. 
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overexpression of either anthrax toxin receptor on cancer cells would likely result in 
significantly higher toxin uptake than the surrounding healthy cells. The high specificity of 
PA for a receptor associated with tumours and interesting translocation machinery has 
generated attention as a potential targeted cancer therapy (72,73).  
 
PA alone is non-toxic, but has been shown to reduce tumour specific angiogenesis (48), 
likely through inhibition of receptor signalling. However, research is generally focused on 
utilising PA to translocate toxins (74,75) and small molecule drugs (76). Recombinant 
proteins that contain the N-terminal region of LF (residues 1 – 254), which facilitates 
binding to PA, linked to cytotoxic domains of other toxins including shiga (77), diphtheria 
(77), and pseudomonas exotoxin A (78) were shown to have specific cytotoxic effects on 
cells that expressed the anthrax toxin receptors. These modified toxins, like the wild type 
anthrax toxins, are inert without the presence of both PA and the anthrax toxin receptors, 
limiting the population of cells that can be affected. With receptor expression directly 
impacting the toxin delivery into cells, and significant over expression of the anthrax toxin 
receptors on a variety of tumour types, it may be possible to use this biological machinery 
to specifically affect cancer cells.  
 
PA targeted delivery as a cancer therapy has focused on two toxins, FP59, a fusion 
protein consisting of the N-terminal region of LF and the catalytic domain III of 
Pseudomonas exotoxin A (78), and anthrax LF. PA in combination with the FP59 toxin 
results in selective killing of human cancer cells without affecting co-cultured healthy cells 
(79) and significant reduction of tumour size observed in murine tumours (80) and human 
xenografts (80,81). This result is due to the receptor expression directly affecting toxin 
internalisation (82). The differential expression of the anthrax toxin receptors controls 
cellular susceptibility to the toxins, only killing cells that are capable of internalising 
sufficient toxin load, an advantageous attribute for reducing toxicity to healthy cells. LF as 
a targeted toxin has similar results to FP59. LF enzymatically cleaves mitogen-activated 
protein kinase (MAPK) kinases, inducing atypical vascular collapse without signs of 
endotoxic shock (83). Although LF is less cytotoxic than FP59 the mechanism by which LF 
affects cells may make it a better candidate for therapeutic purpose. LF reduces 
endothelial cell recruitment and migration in addition to inhibiting ECM remodelling and 
endothelial cell differentiation (84), processes that are essential for tumour growth, 
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angiogenesis, and metastasis (85). Whilst both FP59 and LF have shown potential as 
tumour treatments their selectivity to cancer cells depends entirely on PA.  
 
As PA is capable of binding to two receptors it is important, when attempting to create 
potential therapeutics, to minimise non-target activity. Although TEM8 and CMG2 are over 
expressed in many tumours, PA can still bind TEM8 and CMG2 expressed on healthy 
tissues. One approach to improving biological activity involves tailoring the affinity to a 
specific target. By selectively mutating up to two amino acids of PA it is possible to create 
a functional protein that is selective for either TEM8 or CMG2 (71,86). This approach 
would be particularly advantageous to monitor the expression of each receptor without 
using antibodies. An alternative method of improving specificity to tumour cells has 
involved altering the furin protease cleavage site to a site recognised by tumour associated 
proteases. By modifying PA to be cleaved by the urokinase plasminogen activator (UPA) 
system (79) or matrix metalloproteinases (MMPs) (87) it is possible to limit the 
translocation of toxins to cells that express these proteases. In addition to increasing cell 
specificity, altering the protease site has also shown to increase the serum half-life (88) 
potentially increasing bioavailability and tumour uptake. Combining UPA and MMP 
activated PA into an inter-complementing pore that requires both proteases to be present 
for efficient toxin translocation has also been developed (89). While this approach has 
been shown to improve toxicity and selectivity to some cancers it also reduces the range 
of cancers that can be targeted. It is important to note that there is no comprehensive data 
to suggest the necessity for altering the native PA protein in the development of a 
therapeutic. The relatively low expression of anthrax toxin receptors in healthy tissue 
compared to tumours would likely result in sufficient targeting of a therapeutic. In addition 
to demonstrating broad spectrum tumour targeting, PA could be used as a targeting 
platform for small molecule drugs. By exploiting the toxin translocation machinery to 
specifically target drug conjugates to cancer cells PA could improve current therapies by 
reducing toxicities and improving specificity. To validate PA as a potential targeting agent 
further work is needed to understand in vivo biodistribution and physiological tumour 
targeting capabilities relative to non-specific uptake in healthy tissues.   
 
1.1.7 Protective Antigen is a Potential Tumour Specific Imaging Agent 
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PA is a potentially useful molecular imaging agent for diagnostic or therapeutic purpose. It 
is highly specific for cell surface receptors that have been demonstrated to be 
overexpressed on many cancers, receptors that are involved in key aspects of tumour 
development that could inform on tumour invasion. Additionally, PA is capable of actively 
triggering internalisation into cells amplifying uptake, and can be engineered to improve 
selectivity or function. Although there is currently no data on the tumour selectivity of PA in 
vivo, a PA based peptide labelled with the precursor 4-nitrophenyl 2-18F-fluoropropionate 
was developed as a PET imaging tracer for skin cancers (90). The peptide consisted of 13 
residues from the domain IV binding loop of PA (residues 680-692) responsible for the 
direct interaction between PA domain IV and the receptor MIDAS. Biodistribution analysis 
of the PA peptide resulted in the highest radioactivity in the kidneys and pancreas, 
followed by the lungs and tumour (90). Uptake in the lungs may be due to natural 
expression of the anthrax toxin receptors (91), whether the pancreas also naturally 
expresses these receptors in unknown. There is potential for a PA peptide to bind off 
target collagen binding receptors that share the conserved MIDAS motif. The peptide 
tracer showed enhanced uptake in head and neck squamous cell carcinoma but low 
uptake in melanoma xenografts, consistent with TEM8 expression and degree of tumour 
vascularisation (90), similar to the results observed with an anti-TEM8 antibody. This 
peptide imaging agent is the first study showing the potential of targeting tumours with PA 
based molecules but has limitations due to rapid metabolism and clearance. In order to 
maximise tumour retention and in vivo half-life it was suggested a structural scaffold 
component could be added to the peptide, potentially improving imaging results by 
reducing the rate of degradation (90). Alternatively, using the full length PA protein would 
likely have a similar effect without the potential of altering binding characteristics. 
PA as a molecular imaging probe is likely to have advantages over both antibody and 
peptide approaches.  
 
Similar to an antibody, PA has high specificity to tumour biomarkers but will likely result in 
significantly lower background accumulation in clearance and immune organs due to a 
relatively short serum half-life (92). The shorter serum half-life of PA would also allow for a 
more clinically appropriate imaging window than an antibody, within a day of administration 
of PA versus up to a week for an antibody. The full length PA protein also has advantages 
over a peptide with regards to receptor selectivity. PA binds to two highly conserved 
regions of the anthrax toxin receptors, as the previously described peptide only binds to 
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the receptor MIDAS region there is potential for non-specific binding to other collagen 
receptors. Unlike both antibodies and peptides the full length PA protein is able to form 
complexes with itself, amplifying cellular internalisation of an imaging agent due to a 
greater than 1:1 receptor to imaging molecule ratio. Being a bacterial protein PA is likely to 
have significantly lower production costs, can be readily modified, and has demonstrated 
long term stability in a dried form (93). However, a potential issue of bacterial proteins is 
the possibility of an immunogenic reaction.  
 
Human clinical trials have been performed using recombinant PA produced in an avirulent 
strain of B. anthracis (94) and E. coli (95) demonstrating that PA is well tolerated with no 
serious adverse events after intramuscular administration of escalating doses. While the 
goal of the clinical trials was to assess PA as an anthrax vaccine it was necessary to inject 
multiple doses with immune stimulating adjuvants to produce sufficient immune responses 
(96). These clinical trials demonstrate that an unmodified PA protein is safe to administer 
without causing adverse immune reactions that could risk patients, a first step in 
developing a clinical agent. Overall PA is a promising tumour targeting agent that has 
many unique features that warrants further development and research. 
 
1.1.8 Future Considerations 
 
Due to the highly complex nature of ECM homeostasis and angiogenesis it is difficult to 
fully assess effects of TEM8 and CMG2 in cell-based experiments. The expression of 
TEM8 is generally assessed using in vitro cell cultures but there is a lack of evidence to 
suggest these results have physiological relevance. In vitro experiments have shown that 
the expression of TEM8 is affected by the presence of ECM and growth factors, 
additionally, cells have demonstrated reduced expression over time. Whether the 
differential expression of TEM8 in cell culture versus tumour tissue is due to cellular 
environment or the presence of a vasculature is as yet unknown. As the expression of 
these receptors is significantly affected by environmental conditions, in vitro assays alone 
are not sufficient to determine potential in vivo efficacy. Studies have identified this 
discordance with cancer cells lines that are TEM8 negative in vitro but express TEM8 in 
vivo. Without an appropriate physiological environment, the relevance of receptor 
expression and function in vitro is questionable.  
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More research is required to identify and compare in vitro and in vivo expression of TEM8 
and CMG2 in response to angiogenic factors and ECM stiffness. Future studies will need 
to interpret in vitro results carefully as the complex processes involved in regulating the 
expression of TEM8 and CMG2 in tumours may not be accurately reproduced in cell 
based models. A greater weight needs to be applied to in vivo techniques to assess 
potential tumour biomarkers, particularly those involved in processes that do not occur in 
cell culture models. Molecular imaging techniques can be used to monitor changes in 
expression of potential cancer biomarkers non-invasively, in a physiologically relevant 
tumour environment, providing real time information on potential diagnostic, prognostic or 
therapeutic effects. Targeted molecular imaging is likely to play an important role 
understanding the expression and function of the anthrax toxin receptors during tumour 
development and assess their potential as biomarkers.  
 
As naturally occurring tumours are heterogeneous populations of cells the ability to 
specifically target tumour cells as well as affecting the general tumour environment may 
improve efficacy. Whilst promising results have been published with regards to PA 
targeted toxin based therapies, there are potential immunoreactivity limitations of toxins. It 
is likely that direct drug conjugation would be a more suitable direction for the development 
of a PA based therapeutic, translocating a cytotoxic drug or synthetic peptide. A potential 
alternative direction to PA conjugation is LF N-terminal conjugation. LF N-terminal 
conjugation has been shown to successfully translocate peptides with β-alanine, N-methyl-
alanine, fluoro-phenylalanine, alkyne, and biotin modifications, as well as small molecule 
drugs such as doxorubicin and monomethyl auristatin F (76). Whilst direct conjugation of 
PA is a simpler approach, there is potential to use PA as an imaging agent and only 
administer an LF N-terminal agent after assessment of PA localisation. The ability to 
specifically target molecules to the cytosol of tumour cells may significantly improve 
therapy by reducing toxicity and required doses. A recombinant protein based delivery 
system would be cost effective, with potential to further engineer targeting or retention 
characteristics (97).  
 
A potential limitation of PA is that it is able to bind to two receptors. Whilst it has been 
demonstrated that PA can be modified to be more selective to a single receptor, there is 
currently no evidence to suggest this is necessary. Despite the majority of research 
focusing on TEM8 as a tumour specific biomarker there may be cancers where CMG2 is a 
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more effective target. TEM8 and CMG2 are highly conserved proteins that are involved in 
ECM homeostasis and angiogenesis. It is possible that targeting both receptors at once is 
more advantageous than disadvantageous. Further work is needed to identify and 
characterise TEM8 and CMG2 in vivo, with particular focus on determining uptake of a PA 
based probe in healthy tissue and its potential side effects.  
 
1.1.9 Conclusions 
 
The anthrax toxin receptors are potential biomarkers of tumour specific ECM remodelling 
and angiogenesis. Their selective expression on tumours play a role in facilitating tumour 
development, invasion, and metastatic potential. Targeting these receptors for molecular 
imaging purposes is likely to provide valuable information for diagnostic, prognostic and 
therapeutic purposes. Whilst it is possible to develop antibodies, peptides, or small 
molecules to target these receptors, using the natural exogenous ligand PA has unique 
advantages. PA has been demonstrated to be highly selective to tumours, readily modified 
and re-engineered to focus its selectivity, and presented no adverse immune reactions in 
human clinical trials. PA, targeting the anthrax toxins receptors, is an attractive targeted 
molecular imaging probe that warrants further investigation. 
 
1.2 Significance and Aims 
 
1.2.1 Significance 
 
Identification of potential biomarkers of cancer that link pathological changes in the ECM 
with tumour development and progression would be of significant benefit for diagnostic, 
prognostic and therapeutic applications. The anthrax toxin receptors are highly conserved 
cell surface receptors that principally interact with components of the ECM 
(32,33,35,41,43,98,99), and have been identified to be upregulated in both preclinical 
cancer models (39) and patient derived tumour tissue (22,23,25-27). Thus, the anthrax 
toxin receptors are ideal targets for translatable research between preclinical models and 
clinical applications, and may provide a new means of identifying or targeting cancers. 
 
Whilst there are multiple options for targeting the anthrax toxin receptors, the exogenous 
ligand PA is one potential candidate. PA is a versatile bacterial protein produced by B. 
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anthracis that is highly specific for the anthrax toxin receptors (61,64,100). It has been 
previously demonstrated that PA can be readily modified and is capable of targeting toxins 
(48,72,73,79-81) and small molecules (101) to tumours. Targeting the selective 
overexpression of anthrax toxin receptors observed of numerous tumours, PA could be a 
clinically viable agent for diagnosis or treatment. However, it is not currently known if PA 
exhibits tumour selective localisation in vivo. For PA to be developed as a tumour targeting 
agent, characterisation of in vivo tumour uptake, biodistribution, and clearance 
mechanisms is required. Molecular imaging is a powerful tool for non-invasive real-time 
monitoring of target agents in vivo and can provide valuable information regarding 
biodistribution and clearance of PA.  
 
1.2.2 Aims 
 
My research has focused on the hypothesis that B. anthracis PA is highly specific to 
tumours as a result of selective overexpression of the anthrax toxin receptors. The primary 
aim of the project was to develop and characterise PA as a tumour specific molecular 
imaging agent, utilising a physiologically relevant mouse model of SCC. The specific aims 
of my thesis were: 
 
1. Develop an efficient and reproducible method of producing B. anthracis PA in an E. 
coli expression system using liquid chromatography purification techniques. 
 
2. Use non-specific amine bioconjugation techniques to label PA with a near infra-red 
fluorophore and 89Zr radionuclide chelator for molecular imaging. 
 
3. Characterise the SCC tumour specificity of PA, when administered intravenously, 
using optical and positron emission tomography molecular imaging techniques. 
 
4. Characterise the biodistribution and clearance mechanisms of PA using molecular 
imaging.
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Chapter 2 – Development of Recombinant PA for Molecular Imaging 
 
2.1 Introduction 
 
Protective Antigen (PA) is an 83 kDa protein produced by the gram positive bacterium B. 
anthracis (102), more commonly known as anthrax. PA mediates the binding and 
translocation of anthrax toxins into cells (103) through highly specific interactions with two 
conserved anthrax toxin receptors (61,104). These receptors have been identified to be 
selectively overexpressed on a variety of tumour tissues (28,30,39), thus are potential 
biomarkers of cancer. PA has the potential to be developed as a tumour targeting agent 
for diagnostic or therapeutic purposes, and has been previously demonstrated to target 
toxins to tumours in preclinical models (72,73). While these modified constructs have been 
demonstrated, the routine production of PA in high yield has been less than convincing. To 
assess the potential of PA as a targeting agent, by characterising tumour specificity and 
biological distribution, an efficient and reproducible method of PA production is required. 
Therefore, the first goal of this project was to revisit the expression and purification 
protocols for producing PA.  
 
Recombinant protein production in bacteria is an extremely common method of 
manufacturing proteins for research and commercial purposes, utilising the cellular 
machinery of a chosen organism to generate non-native proteins (105). Recombinant 
protein expression involves the insertion of a DNA sequence encoding a protein of interest 
into an expression vector, often a small circular DNA molecule that can be replicated 
independently known as a plasmid, which is subsequently inserted into cells for protein 
production (106). The DNA sequence of interest can be produced synthetically from a 
known nucleotide sequence or isolated from genomic material of an organism, and 
inserted into an expression vector. The expression vector contains additional genetic 
information encoding antibiotic resistance for selection of cells that can express the protein 
of interest, an origin of replication required for the independent replication of the 
expression vector, and often an inducible promoter sequence to initiate transcription (106). 
Additionally, the expression vector may contain sequences that encode tags for affinity 
purification, solubility enhancement, or subcellular targeting (107). The expression vector 
is then transformed or transfected into an appropriate strain of bacteria for expression of 
the desired protein. 
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There has been extensive research regarding the expression and purification of PA. Initial 
research focused on the potential of PA as a vaccine antigen, providing immunity to 
anthrax infection, using isolates from the culture solute of B. anthracis (108). More 
recently, refinement of recombinant production and purification techniques has led to the 
characterisation of the PA protein structure (63,109) and function (64,69,103,110,111), 
resulting in the determination of receptor binding and anthrax toxin translocation 
mechanisms.  
 
Numerous methods are described in the literature for the expression and isolation of PA, 
summarised in Table 2-1. PA has been generally expressed and isolated from B. anthracis 
(108,112-116), B. subtilis (117,118), and E. coli (68,119-127), but has also been 
successfully produced in a plant expression system (128). Whilst avirulent strains of B. 
anthracis have demonstrated to be the most efficient means of large-scale production of 
PA (113,116), E. coli production has proven to yield sufficient protein for research use. E. 
coli expression has many advantages for protein production. It is a safe, relatively easy, 
and low cost method for producing sufficient protein for research purposes (129). Although 
E. coli has limited capability to produce complex post-translational modifications or 
appropriate disulfide bonds (129), these limitations should not impact expression since PA 
does not appear to undergo any post-translational modifications nor does it contain 
disulfide bonds.  
 
E. coli expression of PA has been reported using plasmids that result in cytoplasmic (120-
122,126) and periplasmic (68,117,119,125,127) localisation of the protein. Periplasmic 
targeting sequences are generally used to express proteins that require the oxidising 
environment of the periplasm for appropriate folding and disulfide bond formation (130) or 
to express proteins that can be toxic when accumulated in the cytoplasm (131), but  may 
also reduce protein degradation and improve soluble protein extraction (129). The first 
report of PA expression in E. coli described both cytoplasmic and periplasmic localisation 
(124). Purification of cytoplasmic PA was initially reported to be unsuccessful due to 
extensive degradation and the difficulty in purifying PA from the comparatively large 
amount of E. coli proteins (124). Periplasmic localisation resulted in improved yield of 
intact PA protein that could be easily isolated compared to cytoplasmic localisation. Yields 
up to 0.5 mg of PA per litre of culture were reported (124).   
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Table 2-1. Summary of Protective Antigen expression and purification. 
Year  Gene sequence 
Expression 
vector Promoter 
Expression 
organism Culture conditions Cell Disruption Fusion Tags Purification 
Yield 
(mg/L) Ref. 
1968 Native — Native 
promoter 
B. anthracis 
Sterne 
“Casamino acids 
medium” 
37°C, 23-27 hrs 
Secreted 
protein 
— (NH₄)₂SO₄ 
precipitation, Gel 
filtration 
8.7 (108) 
1988 Native — Native 
promoter 
B. anthracis 
Sterne 
“RM medium” 
35°C, 18-24 hrs 
Secreted 
protein 
— (NH₄)₂SO₄ 
precipitation, HAC, 
IEX (DEAE) 
20 (115) 
1989 Native  pYS5 (E. coli 
– Bacillus 
fusion vector) 
T7 B. subtilis “FA medium” 
37 °C, N.R. 
Secreted 
protein 
— Antibody affinity  7.5 (118) 
1989 Native  — Native 
promoter 
B. anthracis 
Sterne 
“R medium” 
37°C, 20 hrs 
Secreted 
protein 
— (NH₄)₂SO₄ 
precipitation, IEX 
(Mono-Q) 
N.R. (112) 
1995 Native  pYS5 (E. coli 
– Bacillus 
fusion vector) 
T7 B. anthracis 
BH44 
“FA medium” 
37°C, N.R. 
Secreted 
protein 
— (NH₄)₂SO₄ 
precipitation, HAC,  
IEX (Mono-Q) 
N.R. (114) 
1996 Native  Modified pYS5 
(E. coli)  
T7 E. coli BL21 
(DE3) 
“LB broth”  
1mM IPTG 
37°C, 2 hrs 
Osmotic shock  — (NH₄)₂SO₄ 
precipitation, HAC, 
IEX (DEAE) 
0.5 (124) 
1998 Native pET22b (E. 
coli) 
T7 E. coli BL21 
(DE3) 
“Luria broth” 
1 mM IPTG 
30 °C, 3 hrs 
Osmotic shock — IEX (Q-Sepharose), 
IEX (Mono-Q), Gel 
Filtration 
0.5 (119) 
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1998 Native — Native 
promoter 
B. anthracis 
(Sterne) 
Phosphate buffered, 
tryptone and yeast 
extract based 
medium 
37°C, N.R. 
Secreted 
protein 
— IEX (High Q), HPLC 
IEX (aminopropyl), 
(NH₄)₂SO₄ 
precipitation, HIC 
20-30 (113) 
1998 Native pUB110 (S. 
aureus) 
 
Pcap  
 
B. subtilis 
WB600 
“tryptone based 
medium” 
37°C, 8 hrs 
Secreted 
protein 
— (NH₄)₂SO₄ 
precipitation, IEX 
(DEAE), IEX (Mono-
Q), Gel filtration 
5-7 (117) 
1999 Native  pET22b (E. 
coli) 
T7 E. coli BL21 
(DE3) 
“Luria broth” 
1 mM IPTG  
30°C, 3 hrs 
Osmotic shock — IEX (Q-Sepharose), 
IEX (Mono-Q) 
N.R. (123) 
1999 Native pQE30 (E. 
coli) 
T5 E. coli 
SG13009 
(pREP4) 
“Luria broth” 
1 mM IPTG 
37°C, 5 hrs 
Sonication  N-terminal 6xHis IMAC, IEX (Mono-Q) 2 (121) 
2002 Native  pET22b (E. 
coli) 
T7 E. coli BL21 
(DE3) 
“Luria-Bertani (LB) 
broth” 
1 mM IPTG  
30°C, 3 hrs 
Osmotic shock C-terminal 6xHis IMAC N.R. (68) 
2002 Modified1 pYS5 (E. coli 
– Bacillus 
fusion vector) 
T7 B. anthracis 
BH44 
“FA medium” 
37°C, N.R. 
 
Secreted 
protein 
— (NH₄)₂SO₄ 
precipitation, HIC, IEX 
(Q Sepharose), Gel 
filtration 
113.3-
135.1 
(116) 
2004 Native pET22b (E. 
coli) 
T7 E. coli BL21 
(DE3) 
“ECPM1 medium” 
0.8-1 mM IPTG 
30°C, N.R. 
“periplasm 
extraction” 
— IEX (Q-Sepharose), 
Gel filtration 
N.R. (127) 
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2007 Native  pET22b (E. 
coli) 
T7 E. coli BL21 
(DE3) 
“ECPM1 medium” 
0.8-1 mM IPTG  
30°C, 4 hrs 
Osmotic shock C-terminal 6xHis IMAC, Gel filtration N.R. (125) 
2007 Native  pHMV6g (E. 
coli) 
T7 E. coli BL21 
(DE3) 
N.R. N.R. N-terminal 6xHis, 
maltose-binding 
protein  
IMAC, (NH₄)₂SO₄ 
precipitation, HIC 
N.R. (120) 
2009 Native pET-30a (E. 
coli) 
T7 E. coli 
Rosetta 
2 (DE3) 
“Luria–Bertani” 
0.5 mM IPTG 
30°C, 4 hrs 
Sonication  — (NH₄)₂SO₄ 
precipitation, HIC 
13 (122) 
2013 Modified2 pGRD4 
(Tobacco 
mosaic virus 
vector) 
Prm N. 
benthamiana 
— Homogenisation N-terminal tobacco 
PR-1a signal 
peptide 
C-terminal 6xHis, 
endoplasmic 
reticulum retention 
signal  
IMAC, (NH₄)₂SO₄ 
precipitation, HIC, IEX 
(not specified) 
N.R. (128) 
2016 Native  pQE30 (E. 
coli) 
pPROEXHTa 
(E. coli) 
pET32c (E. 
coli) 
T5 
trc 
T7 
E. coli 
(various) 
“Luria-Bertani broth” 
1 mM IPTG 
Various  
Sonication  N-terminal 6xHis 
(pQE30, 
pPROEXHT) 
N-terminal S-tag, 
6xHis, thioredoxin 
(pET32c) 
IMAC, IEX (DEAE) 1.5-15.1 (126) 
N.R., not reported; IPTG, isopropyl β-D-thiogalactopyranoside; IMAC, immobilised metal affinity chromatography; HAC, hydroxyapatite 
chromatography; HIC, hydrophobic interaction chromatography; IEX, ion exchange chromatography; DEAE, diethylaminoethyl. 1N657A, 
E308D, 164RKKR to 164SNKE, F313 & F314 deletion. 2N-terminal deletion of 30 residues, plant optimised gene sequence. Culture 
conditions report protein expression temperature and duration. Yield represents mg of purified PA per litre of culture.  
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More recent attempts to express PA localised to the cytoplasm have reported significantly 
higher yields than periplasmic localisation (121,122,126). Whilst isolation of PA from E. coli 
cytoplasmic proteins is more difficult, the addition of affinity tags such as 6xHis have been 
demonstrated to aid purification (120,121,126). Purification techniques commonly used to 
isolate PA, includes anion exchange chromatography, hydroxyapatite chromatography, 
hydrophobic interaction chromatography, ammonium sulphate precipitation, and gel 
filtration. 
 
We have expressed and purified PA using an E. coli expression system, utilising 
immobilised metal affinity chromatography (IMAC), anion exchange, and gel filtration liquid 
chromatography purification techniques. The recombinant PA was confirmed to maintain 
receptor binding to recombinant human TEM8. In order to visualise PA in vivo the addition 
of imaging agents is required. Bioconjugation is a common technique for covalently 
attaching imaging molecules such as fluorescent dyes or radionuclide chelators to 
proteins. The two most common protein bioconjugation techniques involved modification of 
sulfhydryl groups or primary amines. As PA does not possess any sulfhydryl groups we 
utilised an amine reactive near infra-red fluorescence dye sulfo-Cyanine5 (Cy5) for protein 
visualisation. The fluorescent PA molecule demonstrated concentration dependant in vitro 
binding to a mouse squamous cell carcinoma cell line, and can be utilised for in vivo 
assessment of tumour specific localisation and distribution.  
 
2.2 Methods 
 
2.2.1 Plasmid constructs 
 
Construct 1 – pHMV6g plasmid (derivative of pET28a) encoding the wild type B. anthracis 
PA gene (minus the N-terminus secretion signal sequence) with N-terminal 6xHis and 
Maltose Binding Protein (MBP) fusion tags, separated by a Tobacco Etch Virus (TEV) 
protease sequence and poly-glycine linker (Fig. 2-1). The construct was obtained from Dr 
J.D. Ballard (University of Oklahoma Health Sciences Center, USA) and has been 
previously reported (120). 
 
Construct 2 – pET-30b (+) plasmid encoding an E. coli optimised PA gene sequence and 
C-terminal 12xHis tag, separated by a TEV protease sequence (Fig. 2-2). Codon 
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optimisation and construct generation was performed by the University of Queensland 
Protein Expression Facility. 
 
Construct 3 – Modified pGEX-4T1 plasmid encoding the extra cellular domain of human 
TEM8, with an N-terminal Glutathione S-Transferase (GST) protein separated by a 
thrombin protease site (Fig. 2-3). The construct was obtained from Dr J.D. Ballard 
(University of Oklahoma Health Sciences Center, USA). 
 
2.2.2 E. coli transformation 
 
Plasmids were transformed into BL21 (DE3) and Rosetta (DE3) E. coli by mixing ~10 ng of 
plasmid with 50 µL of calcium chloride chemically competent cells. The mixture was 
Figure 2-1. Construct 1 protein sequence. 
N-terminal 6xHis affinity tag (red), maltose binding protein (black, underlined), tobacco 
etch virus protease site (green), protective antigen (black). Multiple cloning site is shown in 
blue and non-native linker sequence is shown in purple. * represents stop codons. 
Expression vector, pHMV6g. 
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incubated on ice for 30 minutes, placed in a dry block preheated to 42°C for 45 seconds, 
and returned to ice for 2 minutes. Lysogeny broth (LB, 500 µL) was added to the cell 
solution and incubated at 37°C for 1 hour with shaking. The cell solution was transferred to 
LB agar plates in 50 µL and 150 µL aliquots, containing 50 µg/mL kanamycin and 
incubated overnight at 37°C.  
 
Single colonies from the LB agar plates were inoculated into 10 mL of LB containing 50 
µg/mL kanamycin, incubated at 37°C, with agitation at 220 RPM in a New Brunswick 
incubator shaker (Eppendorf), until optical density at 600 nm (OD600) was 2-3. Optical 
density was measured in a 1 mL cuvette with a NanoDrop 2000c spectrophotometer 
(Thermo Fisher Scientific Inc.). The resulting cell solution was mixed with an equal volume 
of filter sterilised (0.22 µm syringe filter, Merck) glycerol/water solution (50% v/v). The cell 
solution was aliquoted (250 µL), snap frozen with liquid nitrogen and stored at -80°C until 
required.  
 
2.2.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) 
 
Tris glycine gels (12% weight per volume (w/v) bis-acrylamide) were made in house 
following standard protocols. Briefly, 12% resolving gel containing 3 mL bis-acrylamide 
(19:1, 40% w/v), 0.1 mL sodium dodecyl sulfate solution (10% w/v in water), 2.5 mL Tris 
Figure 2-2. Construct 2 protein sequence. 
Protective antigen (black), tobacco etch virus protease site (green), C-terminal 12xHis 
affinity tag (red). * represents stop codons. Expression vector, pET-30b (+). 
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buffer (1.5M, pH 8.8), 4.4 mL water, 50 µL ammonium persulfate solution (10% w/v in 
water), and 10 µL Tetramethylethylenediamine (TEMED) was poured into glass gel-casting 
cassettes (Biorad). Ethanol (100%) was overlayed on the gel solution and left at room 
temperature for ~1 hour to polymerise. The ethanol was poured off and 5% stacking gel 
containing 0.623 mL bis-acrylamide, 0.05 mL sodium dodecyl sulfate solution, 0.63 mL 
Tris buffer (1M, pH 6.8), 3.697 mL water, 50 µL ammonium persulfate solution, and 10 µL 
TEMED was poured on the resolving gel, well comb inserted, and allowed to polymerise. 
Gels were stained with coomassie brilliant blue G250 (Bio-Strategy) in acidified water 
following published procedures (132). The gels were imaged using a Gel Doc EZ System 
(Biorad).  
 
2.2.4 Expression optimisation of 6xHis-MBP-PA 
 
All LB medium contains 50 µg/mL kanamycin sulfate. A starter culture of 10 mL LB was 
inoculated with BL21 E. coli containing 6xHis-MBP-PA expression construct, and 
incubated overnight (37°C, 220 RPM). This starter culture (1 mL) was used to inoculate 
100 mL LB. Again, these cultures were incubated at 37°C, 220 RPM, to OD600 ~0.6, 
cooled to 30°C or 15°C and allowed to stabilise for 1 hour. 1 mL or 100 µL of 1M isopropyl 
β-D-thiogalactopyranoside (IPTG) solution was added to each culture (final concentration 
0.1 mM or 0.01 mM respectively) and incubated overnight at their respective temperatures.  
 
Following overnight incubation, a 1 mL aliquot of the cell culture was pelleted by 
centrifugation (5000 x g for 10 minutes). The cell pellet was resuspended in 200 µL of 
sodium phosphate buffer (20 mM, pH 7.4, 500 mM NaCl). Laemmli buffer (100 µL of 3X) 
Figure 2-3. Construct 3 protein sequence. 
Glutathione s transferase (black, underlined), thrombin protease site (green), extracellular 
domain of tumour endothelial marker 8 (black). * represents stop codons. Expression 
vector, modified pGEX-4T1. 
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was added to the suspension, heated for 10 minutes at 95°C, centrifuged (10000 x g for 5 
minutes) and the supernatant analysed by SDS PAGE. Further expression and purification 
of PA was conducted at 30°C for reasons as discussed below in the results section.  
 
2.2.5 Expression and purification of 6xHis-MBP-PA 
 
BL21 E. coli transfected with the 6xHis-MBP-PA construct was cultured as above using 1 L 
LB in place of 100 mL LB. After induction the cells were pelleted by centrifugation (10000 x 
g for 15 minutes), resuspended in nickel binding buffer (20 mM sodium phosphate, 500 
mM NaCl, 20 mM imidazole, pH 7.4), and sonicated on ice within a fridge for ~30 minutes 
(5s on 10s off) in order to avoid heating the suspension during sonication. The disrupted 
cells were centrifuged (40000 x g for 45 minutes) and the supernatant collected and the 
pellet discarded. 
 
All purification steps were performed at 4°C or on ice. The disrupted cell supernatant was 
filtered using a 0.45 µm syringe filter (Merck) and loaded on a 5 mL HisTrap Fast Flow 
column (GE life sciences), pre-equilibrated with nickel binding buffer (50 mM sodium 
phosphate, 300 mM NaCl, pH 8.0). The column was washed with ~10 column volumes 
(CVs) of nickel binding buffer. The protein was eluted with a further 5 CVs of nickel binding 
buffer containing 500 mM imidazole. This protein solution was buffer exchanged into MBP 
buffer (20 mM Tris, 200 mM NaCl, 1 mM EDTA, pH 7.4) using a 30K MWCO Amicon Ultra-
10 Centrifugal Filter (Merck).  
 
The protein sample was loaded on a 5 mL MBPtrap Fast Flow column (GE life sciences), 
pre-equilibrated with MBP buffer. The column was washed with ~10 CVs of MBP buffer 
and eluted with 5 CVs of MBP buffer containing 10 mM maltose.   
 
TEV protease (1 mg in 10 mM Tris, 10 mM NaCl, 1 mM TCEP, pH 7.6), was added to the 
protein and incubated at 4°C overnight.  
 
The cleaved protein was eluted through a 5 mL HisTrap Fast Flow column (GE life 
sciences) pre-equilibrated with MBP buffer, the flowthrough collected, buffer exchanged 
into 10 mM Tris pH 8.0 and eluted through a 1 mL mono Q anion exchange column (GE 
life sciences) pre-equilibrated with 10 mM Tris pH 8.0. A linear gradient of NaCl (0-500 mM 
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in 10 mM Tris pH 8.0 buffer) over 20 CVs was used to elute the protein. Fractions that 
contained the protein of interest, as determined by SDS PAGE, were pooled and 
concentrated to less than 1 mL using an 30K MWCO Amicon Ultra-10 Centrifugal Filter 
(Merck). 
 
Further purification was performed using a Superdex 200 Increase 10/300 GL column (GE 
life sciences) at a flow rate of 0.15 mL/min and injection volume of 250 µL. The fractions 
which contained the PA protein were pooled, concentrated, and reapplied to the column. 
Fractions with the highest purity determined by SDS PAGE were pooled, concentrated, 
and stored at 4°C. 
 
2.2.6 Comparison of 6xHis-MBP-PA expression in BL21 and Rosetta E. coli 
 
BL21 or Rosetta E. coli containing the 6xHis-MBP-PA expression construct were cultured 
as previously described in 2.2.4 Expression optimisation of 6xHis-MBP-PA. When the 
OD600 reached ~0.6, the cultures were transferred to 37°C or 25°C and allowed to stabilise 
for 1 hour. IPTG solution (1 mL or 100 µl, 1 M) was added to the cultures and incubated 
overnight. 
 
Each culture was pelleted by centrifugation, resuspended in nickel binding buffer, 
sonicated, protein supernatant isolated, and purified by nickel affinity chromatography as 
described above. Elution fractions from each culture condition were compared by SDS 
PAGE.  
 
2.2.7 Expression and purification of PA-12xHis 
 
BL21 E. coli transfected with the PA-12xHis construct was cultured as described in “2.2.5 
Expression and purification of 6xHis-MBP-PA”. 
 
After induction the cells were pelleted by centrifugation (10000 x g for 15 minutes), 
resuspended in lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 1 mM dithiothreitol, 
200 µg/mL lysozyme, 1% triton X100, pH 8.0), and sonicated as described above. The 
disrupted cells were centrifuged (40000 x g for 45 minutes) and the supernatant collected. 
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All purification steps were performed at 4°C or on ice. The disrupted cell supernatant was 
filtered using a 0.45 µm syringe filter (Merck) and loaded on a 5 mL HisTrap Fast Flow 
column (GE life sciences), pre-equilibrated with phosphate buffer (50 mM sodium 
phosphate, 300 mM NaCl, pH 8.0). The column was washed with ~10 column volumes 
(CVs) of phosphate buffer containing 100 mM imidazole. The protein was eluted with ~5 
CVs of phosphate buffer containing 250 mM imidazole, and buffer exchanged into 
phosphate buffer using a 30K MWCO Amicon Ultra-10 Centrifugal Filter (Merck).  
 
TEV protease (1 mg) was added to the protein and incubated at 4°C for 2 days. The 
cleaved protein was loaded on a 5 mL HisTrap Fast Flow column (GE life sciences) pre-
equilibrated with phosphate buffer, and flowthrough collected. The flowthrough protein 
sample was buffer exchanged into 10 mM Tris pH 8.0 and loaded on a 1 mL mono Q or 5 
mL diethylaminoethyl (DEAE) anion exchange column (GE life sciences) pre-equilibrated 
with 10 mM Tris pH 8.0. Protein was eluted from the anion exchange columns using a 
linear gradient of NaCl (0-500 mM). Fractions that contained the protein of interest, 
determined using SDS PAGE were pooled and concentrated to less than 1 mL. 
 
Further purification was performed using a Superdex 200 Increase 10/300 GL column (GE 
life sciences) as described above. The fractions that contained the PA protein, determined 
using SDS PAGE, were pooled, concentrated, and stored at 4°C.   
 
2.2.8 Dye conjugation 
 
100 µg of sulfo-Cyanine5 (Cy5) NHS ester (Lumiprobe) was dissolved in 25 µL of dimethyl 
sulfoxide, and diluted to 100 µL with water. 900 µL of recombinant PA protein (1-2 mg/ml) 
in 50 mM sodium phosphate pH 8 was added to the dye solution, vortexed, and stored at 
4°C overnight. The unreacted dye was removed using a 10K MWCO Amicon Ultra-4 
Centrifugal Filter (Merck). 
 
2.2.9 Fluorescence imaging of SDS PAGE gel 
 
SDS PAGE was performed on samples of conjugated and unconjugated PA. The gel was 
washed with water and imaged using a Bruker Carestream In Vivo MS FX Pro with the 
following settings. 630 nm excitation, 5 seconds exposure, aperture (f stop) 2.8, field of 
32 
 
view 190 mm2, in 4 x 4 bins, 700 nm emission filter. The gel was then stained with 
coomassie dye and imaged using a Gel Doc EZ System (Biorad). 
 
2.2.10 UV absorbance measurements 
 
The UV absorbance of each sample (2 µL volume) was measured with a Nanodrop2000c 
(Thermo Fisher) UV-Vis spectrophotometer, using the “protein and dye” setting. The 
absorbance of each sample was measured between 220 nm and 750 nm, at 1 nm 
intervals. The extinction coefficient of PA was estimated to be 81710 L mol-1 cm-1 using 
the Edelhoch method (1). Sulfo-Cyanine 5 dye extinction coefficient was 271000 L mol-1 
cm-1, as per the manufacturer’s specifications. 
 
2.2.11 Degree of labelling calculation 
 
The number of dye molecules per protein molecule was calculated using the following 
equation. 
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝐿𝑎𝑏𝑒𝑙𝑙𝑖𝑛𝑔 ൌ
𝐴௠௔௫ ∙ 𝜀
ሺ𝐴ଶ଼଴ െ 𝐴௠௔௫ ∙ 𝐶𝐹ଶ଼଴ሻ ∙ 𝜀′
 
Where, 
𝐴௠௔௫ ൌ 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 650 𝑛𝑚 
𝐴ଶ଼଴ ൌ 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 280𝑛𝑚 
𝜀 ൌ 𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑃𝐴 𝑎𝑡 280 𝑛𝑚 
𝜀ᇱ ൌ 𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑠𝑢𝑙𝑓𝑜 െ 𝐶𝑦5 𝑎𝑡 650 𝑛𝑚 
𝐶𝐹ଶ଼଴ ൌ 𝐷𝑦𝑒 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑎𝑡 280𝑛𝑚 ൌ
𝐴ଶ଼଴
𝐴௠௔௫
𝑜𝑓 𝑡ℎ𝑒 𝑓𝑟𝑒𝑒 𝑑𝑦𝑒  
 
 
2.2.12 Trypsin digestion 
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20 µg of trypsin from porcine pancreas (Sigma) was dissolved in 20 µL of 1 mM hydrochloric 
acid in water. 1 µL of the trypsin solution (1 µg) was added to 100 µL of PA-Cy5 in 50 mM 
sodium phosphate pH 8 and incubated at 37°C. 
 
2.2.13 Fluorescence measurements 
 
Fluorescence measurements were performed using an Infinite® 200 PRO (Tecan) plate 
reader and a transparent Nunclon flat bottom 96 well plate (Thermo Fischer), using the 
following settings. Temperature, 37°C; Mode, fluorescence top reading; Excitation 
wavelength, 630 nm; Emission wavelength, 700 nm; Excitation bandwidth, 9 nm, Emission 
bandwidth, 20 nm; Gain, 86; Integration time, 20 µsec; Lag time 0 µsex; Settle time, 0 
µsec; Z-position, 20017 µm. Sample volume per well was 100 µL. 
 
2.2.14 Expression of GST-TEM8 
 
LB containing 100 µg/mL ampicillin was inoculated with BL21 E. coli containing the GST-
TEM8 construct. The culture was grown at 37°C, 220 RPM, until the OD600 reached 0.6. 
The temperature was reduced to 22°C and allowed to equilibrate. 1 mL of 1 M IPTG 
solution was added to the culture and incubated overnight.  
 
The cells were pelleted by centrifugation (10000 x g for 15 minutes) and resuspended in 
GST Buffer (100 mM Tris, 300 mM NaCl, 5 mM EDTA, pH 8.2). The cells were sonicated 
and centrifuged as described above. All purification steps were performed at 4°C or on ice. 
The supernatant was added to a pre-equilibrated 5 ml GSTrap FF column (GE life 
sciences). The column was washed with 10 CVs GST Buffer, and eluted with GST Buffer 
containing 10 mM reduced glutathione. The eluted protein was buffer exchanged into 
phosphate buffer (50 mM sodium phosphate, 300 mM NaCl, pH 8.0) using a 10K MWCO 
Amicon Ultra-10 Centrifugal Filter (Merck). 
 
2.2.15 Protein binding kinetics 
 
Protein binding kinetics were measured using a BLItz instrument (ForteBio) and BLItz Pro 
software following the manufacturer’s instructions. All proteins were buffer exchanged to 
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phosphate buffer (50 mM sodium phosphate, 300 mM NaCl, pH 8.0) prior to the 
experiment using 10K MWCO Amicon Ultra-4 Centrifugal Filters (Merck). Anti-GST 
biosensors (ForteBio) were hydrated for 10 minutes in phosphate buffer. The biosensor 
was placed in 250 µL of phosphate buffer for 30 seconds as a baseline. 4 µL of the GST-
TEM8 fusion protein solution (1 mg/ml) was loaded on the biosensor for 120 seconds. The 
sensor was placed in 250 µL of buffer for 30 seconds to obtain a baseline. 4 µL of purified 
PA protein was loaded onto the biosensor for 120 seconds to measure association. The 
biosensor was then placed in 250 µL of buffer for 120 seconds to measure dissociation. 
The results were analysed using the BLItz Pro software (ForteBio). 
 
2.2.16 Flow Cytometry 
 
The HPV38E6E7 mouse squamous cell carcinoma (SCC) cell line, obtained from Dr J. W. 
Wells (University of Queensland, Australia), was cultured in a modified F12 media 
supplemented with Dulbecco's Modified Eagle Medium and Fetal Calf Serum (FCS) in a 
37°C incubator containing 5% CO2. The media was removed, and the cells washed with 
phosphate buffered saline (PBS). Pre-warmed trypsin was added to cells and incubated at 
37°C for 5 minutes. The trypsinised cells were harvested, and centrifuged (160 x g for 10 
minutes) at 4°C. The cells were resuspended in 1 mL of PBS, centrifuged (160 x g for 10 
minutes), and resuspended in 5 mL of PBS. 20 µL of cells was mixed with 20 µL of trypan 
blue and counted using a haemocytometer. The cells were centrifuged, resuspended at a 
concentration of 5 x 106 cells per mL, and aliquoted into 100 µL samples. Fc Block 
(Biolegend) was added to the cells at a concentration of 1:300 and incubated on ice for 10 
minutes. PA-Cy5 was added to the aliquots at a final concentration of 1200, 600, 300, 150, 
75, 37.5, 18.8, and 9.4 nM and incubated on ice for 30 minutes. The cells were 
centrifuged, washed with 100 µL of FACS buffer (PBS containing 10% FCS), centrifuged 
again, and resuspended in 100 µL of FACS buffer. Zombie Aqua (Biolegend) dye was 
used for determination of live/dead cell populations as per the manufacturer’s instructions. 
Flow cytometry was performed using an LSRFortessa X-20 cell analyser system (BD 
Biosciecnes) and data analysed using FlowJo software (Tree Star Inc.). 
 
2.3 Results 
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2.3.1 Expression and purification of PA 
 
Expression of 6xHis-MBP-PA in BL21 E. coli was performed at 30°C and 15°C, with 0.1 
mM and 0.01 mM IPTG to identify optimal induction conditions (Fig. 2-4). At both induction 
temperatures 0.1 mM IPTG produced higher expression of the 127 kDa 6xHis-MBP-PA 
fusion protein, with 30°C demonstrating the highest expression. Initial purification by 
immobilised metal affinity chromatography (IMAC) resulted in the isolation of multiple 
highly expressed proteins of varying molecular weights (Fig. 2-5A). Amylose affinity 
chromatography was performed to further isolate the MBP containing protein of interest 
(Fig. 2-5B), but did not result in any observable isolation. This suggests that a significant 
portion of the expressed proteins are truncated fusion proteins containing the N-terminal 
6xHis-MBP and a portion of PA.  
 
The PA protein was cleaved from the 6xHis-MBP affinity tag using Tobacco Etch Virus 
(TEV) protease and further purified by reverse IMAC. Cleavage of the protein sample 
results in a significant shift in two of the three most prominent bands from high to low 
molecular weights, which resulted in protein bands consistent with the expected 83 kDa 
PA and the 44 kDa 6xHis-MBP (Fig. 2-5C). TEV cleavage was extremely efficient, with 
complete cleavage observed within 30 minutes. Reverse IMAC was able to isolate the 83 
kDa PA from the 44kDa 6xHis-MBP tag, but impurities still remained. To further purify the 
Figure 2-4. Optimization of 6xHis-MBP-PA expression conditions. 
1. Protein Marker. 2. BL21 30°C non-induced (concentrated). 3. BL21 30°C non-induced. 
4. BL21 30°C, 0.1 mM IPTG. 5. BL21 30°C, 0.01 mM IPTG. 6. BL21 15°C non-induced 
(concentrated). 7. BL21 15°C non-induced. 8. BL21 15°C, 0.1 mM IPTG. 9. BL21 15°C, 
0.01 mM IPTG. 6xHis-MBP-PA, 127 kDa (red arrow). 
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PA protein strong anion exchange chromatography was performed using a linear gradient 
of sodium chloride, resulting in no observable separation (Fig. 2-6).  
 
Analytical size exclusion chromatography was used to refine the PA protein. PA 
consistently elutes ~14 mL after injection as the most significant peak. SDS PAGE 
analysis demonstrates that this method is able to remove the most significant low 
Figure 2-5. Purification of 6xHis-MBP-PA. 
SDS PAGE of immobilized metal affinity chromatography (IMAC) purification (A). 1. 
Protein Marker. 2. Protein extract. 3. IMAC flowthrough. 4. IMAC wash 5. IMAC elution. 
SDS PAGE of amylose affinity purification (B). 1. Protein Marker. 2. IMAC elution. 3. Buffer 
exchanged into MBP binding buffer 4. Amylose affinity flowthrough (1) 5. Amylose affinity 
flowthrough (2). 6. Amylose affinity wash (1). 7. Amylose affinity wash (2). 8. Amylose 
affinity elution. SDS PAGE of TEV cleavage and reverse nickel affinity purification (C). 1. 
Protein Marker. 2. Amylose affinity elution. 3. TEV cleavage (30 min). 4. TEV cleavage (60 
min). 5. TEV cleavage (90 min). 6. IMAC flowthrough post cleavage. 7. IMAC flowthrough 
post cleavage (concentrated). 8. IMAC elution post cleavage. 6xHis-MBP-PA, 127 kDa 
(red arrow); PA, 83 kDA (purple arrow); 6xHis-MBP, 44 kDa (green arrow). 
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molecular weight proteins and larger aggregates (Fig. 2-7). Pooling the fractions with the 
highest PA purity resulted in a final yield of ~0.25 mg/L of culture, insufficient for in vitro or 
in vivo studies.  
 
As the 6xHis-MBP-PA construct contains the native B. anthracis PA gene sequence, it 
contains codons that are present in low quantities in E. coli. To identify if higher yields 
could be achieved by reducing the expression of truncated products, the expression of 
6xHis-MBP-PA construct was compared in BL21 and Rosetta strains of E. coli. Rosetta 
contains additional plasmids that encode for rare codons to improve expression efficiency. 
Expression was performed at two temperatures and two concentrations of IPTG, analysed 
by SDS PAGE after IMAC purification. In all conditions tested, Rosetta E. coli showed no 
improvement in expression nor reduction of truncated products compared to BL21 E. coli 
(Fig. 2-8).  
 
To improve the production of PA a second expression construct was produced that 
contains an E. coli codon optimised nucleotide sequence, with a C-terminal 12xHis affinity 
tag replacing the N-terminal 6xHis-MBP. The two PA constructs were analysed using the 
GenScript Rare Codon Analysis Tool (133). The PA-12xHis construct had an improved 
codon adaptation index (CAI) of 0.93 versus 0.63 for the original construct, slightly 
increased guanine-cytosine (GC) nucleotide content, and no rare codons (Table 2-2).  
Expression of the PA-12xHis was performed under the same conditions as the previous 
PA construct. Initial purification by IMAC resulted in significant PA-12xHis expression, with 
a distinct band associated with 85 kDa fusion protein (Fig. 2-9A). The IMAC eluted protein 
was cleaved using TEV protease and further purified by reverse IMAC (Fig. 2-9B). The 
cleavage efficiency of this fusion protein was significantly lower than the previous construct 
and required additional protease incubation time. To improve purification anion exchange 
chromatography was performed using weak and strong anion exchange. The majority of 
Table 2-2. Analysis of Protective Antigen gene codon composition. 
Construct Codon Adaptation Index (CAI) GC content (%) 
Low frequency 
codon (%) 
6His-MBP-PA 0.63 33.43 12 
12His-PA 0.93 43.91 0 
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the PA protein elutes from the weak anion exchange column at ~75 mM sodium chloride 
(Fig. 2-10A-B). Although strong anion exchange also produced a clear peak at ~75 mM 
sodium chloride, SDS PAGE demonstrated that there is was no discernible protein 
separation (Fig. 2-10C-D).  
 
The weak anion exchange chromatography fractions containing the majority of the PA 
protein were concentrated and further purified by analytical size exclusion 
chromatography. The majority of the PA protein consistently elutes from the size exclusion 
column as the major peak at ~13.5 mL (Fig. 2-11). This construct demonstrated 
significantly improved expression and purification results yielding 1.5 mg/L of culture.  
The recombinant PA was confirmed to retain binding affinity to a recombinant human 
anthrax toxin receptor, TEM8, using bio-layer light interferometry. A fusion protein of 
glutathione s transferase (GST) and the extracellular domain of human TEM8, produced in 
E. coli, was immobilised on an anti-GST chip to determine the binding kinetics of 
recombinant PA. The experiment was performed in triplicate for a single concentration and 
as a series of dilutions, resulting in binding affinities of 62 nM and 82.4 nM respectively 
(Table 2-3).  
Figure 2-6. Mono Q anion exchange was unable to isolate PA from degradation 
products. 
Chromatogram of anion exchange purification (A). Protein was eluted using increasing 
concentration of sodium chloride (0-500 mM) over 10 column volumes. SDS PAGE of 
anion exchange purification (B). 1. Protein Marker. 2. Initial protein sample. 3. Mono Q 
anion exchange elution (pooled). PA, 83 kDA (purple arrow). 
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2.3.2 Bioconjugation of PA 
 
The purified PA protein was conjugated with an amine reactive sulfo-Cyanine5 (Cy5) near 
infrared fluorescent dye, and PA association confirmed using SDS-PAGE and 
fluorescence imaging (Fig. 2-12). The UV absorbance of unconjugated PA, PA-Cy5, and 
hydrolysed dye was measured between 220 nm and 750 nm (Fig. 2-13A). All three 
samples demonstrate high absorbance at 220 nm due to peptide bonds. The unlabelled 
PA protein has a peak at 280 nm associated with its aromatic amino acids and no 
absorbance beyond 300 nm. Hydrolysed dye resulted in a maximum absorbance at 650 
nm, with a vibrational shoulder visible at 600 nm and lower absorbance peaks at 260 nm 
and 330 nm. PA-Cy5 showed absorbance between 500 nm and 750 nm, with a peak at 
650 nm consistent with maximum absorbance of the dye. The PA-Cy5 sample resulted in 
a second peak at 604 nm in place of the vibrational shoulder observed in the free dye 
sample, as well as lower absorbance peaks at 280 nm, 330 nm, and 365 nm. Serial 
dilution of the PA-Cy5 sample demonstrated that concentration does not affect the 
absorbance spectrum profile (Fig. 2-13B).   
 
Table 2-3. Confirmation of recombinant PA binding to TEM8 
PA 
(µM) 
KD 
(nM) 
ka 
(1/Ms) 
ka 
error 
kd 
(1/s) 
kd 
error Rmax 
Rmax 
error 
R 
equilibrium X
2 R2 
1.16 82 28200 2140 0.0023 0.00019 0.4839 0.03284 0.452 0.254 0.942 
1.16 48.4 57300 2720 0.0028 0.00028 0.3608 0.01518 0.3463 0.260 0.871 
1.16 77.9 43500 2520 0.0034 0.00022 0.4834 0.02251 0.453 0.279 0.918 
global 62 42200 2090 0.0026 0.00020 0.4665 0.02246 0.4428 1.038 0.908 
           
4.55 47.3 22800 382 0.0011 0.00006 1.543 0.02291 1.527 0.348 0.992 
2.99 527 9280 644 0.0049 0.00026 0.7481 0.04527 0.636 0.666 0.917 
2.27 53.1 20100 1050 0.0011 0.00009 0.8692 0.04102 0.849 0.305 0.983 
1.79 121 53600 1650 0.0064 0.00045 0.2987 0.00522 0.280 0.513 0.726 
global 82.4 20100 791 0.0017 0.00012 0.2943 0.00630 0.281 2.20 0.995 
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The degree of labelling was quantified using 81710 L mol-1 cm-1 as the molar extinction 
coefficient of PA, 271000 L mol-1 cm-1 dye extinction coefficient, and dye correction factor 
of 0.076. The dye correction factor at 280 nm was determined experimentally measuring 
the hydrolysed dye absorbance at 650 nm and 280 nm. The degree of labelling was 
calculated to be 4.5 molecules of dye per molecule of PA.  
 
Fluorescence analysis was performed at several concentrations of PA-Cy5 and free Cy5 
dye to identify a relationship between fluorescence and dye absorbance at 650 nm. Both 
PA-Cy5 and free Cy5 dye demonstrated exponential relationships between fluorescence 
and absorbance, with free Cy5 demonstrating approximately 10 fold higher fluorescence 
than PA-Cy5 (Fig. 2-14A). Trypsin digestion of the PA-Cy5 protein resulted in an increased 
Figure 2-7. Size exclusion chromatography purification of PA. 
Absorbance chromatograms of size exclusion purification (A) Dotted vertical lines 
represent fractions. Shaded fractions were pooled for further use. SDS PAGE of size 
exclusion purification fractions (B). 1. Protein Marker. 2. Initial protein sample. Lanes 3 – 
10, fractions one to eight respectively. (C). 1. Protein Marker. 2. Initial protein sample. 
Lanes 3 – 7, fraction nine to thirteen respectively. PA, 83 kDA (purple arrow). 
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fluorescence over time (Fig. 2-14B). After complete digestion the fluorescence signal was 
approximately 10 fold higher than observed prior to digestion (Fig. 2-14C), consistent with 
the fluorescence difference observed between PA-Cy5 and free Cy5. UV absorbance was 
performed before and after trypsin digestion demonstrating an increase in absorbance at 
650 nm and decrease at 604 nm, displaying an absorbance spectrum closer to free Cy5 
(Fig. 2-14D). The degree of labelling was recalculated using the absorbance 
measurements after trypsin digestion, which resulted in ~11.75 molecules of dye per 
molecule of PA. 
 
To confirm PA-Cy5 maintains cell binding, mouse squamous cell carcinoma cells were 
incubated with a series of PA-Cy5 concentrations and analysed by flow cytometry. PA-Cy5 
demonstrated a concentration dependant increase in percentage of cells positive for Cy5 
fluorescence and median fluorescence intensity (Fig. 2-15). At concentrations of PA-Cy5 
300 nM and above 100% of cells were observed to be Cy5 positive, while the median 
fluorescence intensity increased linearly with all tested concentrations.  
 
2.4 Discussion 
 
Figure 2-8. Comparison of Rosetta and BL21 expression of 6xHis-MBP-PA after 
IMAC purification. 
1. Protein Marker. 2. Rosetta 37°C, 0.1 mM IPTG. 3. Rosetta 37°C, 0.01 mM IPTG. 4. 
Rosetta 25°C, 0.1 mM IPTG. 5. Rosetta 25°C, 0.01 mM IPTG. 6. BL21 37°C, 0.1 mM 
IPTG. 7. BL21 37°C, 0.01 mM IPTG. 8. BL21 25°C, 0.1 mM IPTG. 9. BL21 25°C, 0.01 mM 
IPTG. 6xHis-MBP-PA, 127 kDa (red arrow). 
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Fermentation expression of recombinant proteins using E. coli is a widely used and 
versatile method (134). Often proteins are produced as fusion constructs containing 
solubility enhancers and affinity tags for protein isolation. Initially PA was expressed as an 
MBP fusion construct, generally used to increase the solubility of proteins for efficient high 
yield expression (135), in addition to a 6xHis tag for purification by IMAC.  
 
IMAC of the 6xHis-MBP-PA expression construct resulted in the purification of several 
protein products in addition to the protein of interest. In order to isolate the 6xHis-MBP-PA 
protein, amylose affinity chromatography was performed. Although the amylose affinity 
column was overloaded, resulting in fusion protein present in the flowthrough and wash 
fractions, the elution demonstrates that multiple MBP containing protein products were 
expressed. After TEV cleavage there is an obvious shift in the two highest molecular 
weight bands demonstrating that in addition to producing the full fusion protein, there was 
significant expression of truncated products that contain 6xHis-MBP. In addition to the full-
length fusion construct there is significant expression of 70 kDa and 44 kDa proteins, 
suggesting that there are specific regions within the construct that causes truncation. 
Figure 2-9. Purification of PA-12xHis. 
SDS PAGE of IMAC purification (A). 1. Protein Marker. 2. Non-induced. 3. Induced. 4. 
Insoluble. 5. IMAC flowthrough. 6. IMAC wash 7. IMAC elution. SDS PAGE of reverse 
IMAC purification (B). 1. Protein Marker. 2. PA cleaved. 3. PA cleaved IMAC flowthrough. 
4. PA cleaved IMAC elution. PA, 83 kDA (purple arrow). 
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There could be multiple reasons for the expression of truncated proteins, the most likely 
cause is regions of rare codons in the gene sequence causing a disruption of protein 
translation (136). To isolate the 83 kDa PA protein from truncated products strong anion 
exchange and analytical size exclusion chromatography were utilised. Whilst strong anion 
exchange failed to produce separation, size exclusion resulted in isolation of the majority 
of the full length PA protein. Unfortunately, the final protein yield was not sufficient for 
future in vitro or in vivo studies. In an attempt to reduce the expression of truncated 
Figure 2-10. Comparison of mono Q and DEAE anion exchange purification of PA. 
Absorbance chromatogram of DEAE anion exchange purification (A). Protein was eluted 
using increasing concentration of sodium chloride (0-500 mM) over 20 column volumes. 
Dotted vertical lines represent fractions. Shaded fractions were pooled for further use. 
SDS PAGE of DEAE anion exchange purification (B). 1. Protein Marker. 2. Initial sample. 
Lanes 3 – 15, fractions one to thirteen respectively. Absorbance chromatogram of mono Q 
anion exchange purification (C). Protein was eluted using increasing concentration of 
sodium chloride (0-500 mM) over 40 column volumes. Dotted vertical lines represent 
fractions. SDS PAGE of mono Q anion exchange purification (D). 1. Protein Marker. 2. 
Initial sample. Lanes 3 – 10, fractions one to eight respectively. PA, 83 kDA (purple arrow). 
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products the expression construct was transfected into Rosetta E. coli, which contains 
additional plasmids encoding rare codon tRNAs (137), but did not result in an observable 
reduction in truncated products.   
 
To improve the protein yield, the expression construct was modified addressing two 
aspects. Firstly, to minimise the effects of rare codons, the PA gene was altered from a 
wild type B. anthracis nucleotide sequence to an E. coli optimised sequence. This change 
does not alter the amino acid sequence but utilises the most abundant codons for efficient 
protein expression. Secondly, the N-terminal 6xHis-MBP tag and poly-glycine linker were 
removed and replaced with a C-terminal 12xHis tag. By placing the affinity tag at the C-
terminal only the full-length protein will be captured by IMAC. The longer 12xHis tag has a 
higher affinity for the nickel column than the 6xHis tag and should allow for improved IMAC 
purification. A potential drawback of C-terminal constructs is the remnants of non-native 
residues from the protease sequence. Whilst the removal of amino acids at the C terminus 
has demonstrated detrimental effects (138), likely through disruption of intramolecular 
stabilising interactions affecting the domain four binding loop (100), cysteine modification 
and biotinylation does not affect PA binding. As the C-terminus of PA is significantly 
removed from areas which affect binding and function, additional residues at the C-
terminal are not detrimental to PA (139). Removal of MBP is unlikely to negatively affect 
Figure 2-11. Size exclusion chromatography purification of PA. 
Absorbance chromatogram of size exclusion purification (A). Dotted vertical lines 
represent fractions. Shaded fractions were pooled for further use. SDS PAGE of size 
exclusion purification 1 fractions (B). 1. Protein Marker. Lanes 2 – 9, fractions one – eight 
respectively. PA, 83 kDA (purple arrow). 
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expression, as PA has been previously demonstrated to express well in E. coli cells 
without solubility enhancement (126).  
 
The 6xHis-MBP-PA and PA-12xHis constructs were compared using rare codon analysis, 
which uses three measures to predict protein expression efficiency. CAI assesses a 
protein sequence with respect to known highly expressed gene sequences resulting in a 
value between 0 and 1 (140), where values greater than 0.8 are considered optimal. 
Increased GC content has been associated with improvements in expression of proteins, 
however the relationship between gene expression and GC content alone is unlikely to be 
a predictive measure (141,142). As different organisms vary in their codon usage bias, the 
presence of uncommon codons in non-native gene sequences can result in reduced rate 
of translation elongation and potential disruption to translation (141). Modifying the gene 
sequence to the most abundant E. coli codons will likely improve protein expression. The 
PA-12xHis construct has an improved CAI of 0.93, 43.91% GC content, and no rare codon 
usage compared to the 6xHis-MBP-PA constructs CAI of 0.63, 33.43% GC content, and 
12% rare codon usage. These modifications should produce a more efficient expression 
construct, providing a higher recombinant PA yield.  
 
The PA-12xHis construct demonstrated improved expression compared to the 6xHis-MBP-
PA construct. Similar to the previous construct strong anion exchange was unable to 
Figure 2-12. Fluorescence is associated with the PA protein after dye conjugation. 
Coomassie stained SDS PAGE (A). Fluorescence image of unstained SDS PAGE (B). 1. 
PA-Cy5 (PA-12xHis construct). 2. PA-Cy5 (6xHis-MBP-PA construct). 3. Unlabelled PA 
(PA-12xHis construct). Fluorescence image was obtained using a Bruker Carestream In 
Vivo MS FX Pro, excitation 630 nm, emission 700 nm. 
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produce separation of the PA protein of interest, likely due to similarly charged proteins 
present. Weak anion exchange, which is able to provide a greater separation of similarly 
charged proteins (143) resulted in further purification of PA. The final purification was 
performed using analytical size exclusion chromatography to produce a final yield of 1.5 
mg/L of culture and a purity of ~90%.   
 
To confirm that the recombinant PA was appropriately folded, binding kinetics metrics 
were determined using the extracellular domain of human TEM8 by biolayer interferometry 
(BLI). BLI is an optical based method of measuring and detecting binding interactions by 
associating changes in the pattern of white light interference with bound molecules (144). 
The recombinant TEM8 protein, produced as a GST-TEM8 fusion construct, was 
immobilised on anti-GST biosensors and the association and dissociation of PA was 
measured to determine binding affinity (Table 2-2). The observed binding affinity of ~70 
nM was similar to the surface plasmon resonance results presented in the literature (145) 
confirming that the expressed PA maintains binding affinity to its receptors.  
 
Bioconjugation of proteins with imaging agents such as fluorophores is a common 
approach to visualise cellular interactions in vitro, and in vivo distribution in preclinical 
animal models (146). The sulfo-Cyanine 5 (Cy5) dye with amine reactive N-hydroxy 
succinimide (NHS) ester functionality was chosen to label PA. Cy5 has a near infrared 
emission which can be used for common in vitro microscopy and in vivo optical imaging 
techniques. The sulfonation of the dye improves its solubility in water compared to the 
Figure 2-13. UV absorbance confirms PA labelling with sulfo-Cy5. 
Comparison of free sulfo-Cy5 dye (black dash), PA-Cy5 (red solid), and unlabelled PA 
(green solid) UV absorbance (A). Two-fold serial dilutions of PA-Cy5 (B). 
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non-sulfonated analogue without resulting in significant lipid interaction (147), and renders 
the dye cell impermeable due to the negative charge (148). A cell impermeable dye has 
two advantages, limiting non-specific uptake of the dye and preventing diffusion out of a 
cell once internalised. As PA is known to activate its own internalisation through receptor 
mediated processes (44,45,149), a cell impermeable dye will provide greater contrast 
based on the expression of the anthrax toxin receptors. The NHS ester is a common 
conjugation method which reacts with free amines in favourable reaction conditions for 
proteins (150). Whilst amine modification is a nonspecific approach to protein modification, 
based on the known structure of PA the location of solvent exposed amines is sufficiently 
far away from the key regions that interact with the anthrax toxin receptors (Fig. 2-16). 
 
UV absorbance of the PA-Cy5 conjugated protein was used to determine the degree of 
labelling. Generally, the degree of labelling is quantified using the absorbance of the 
protein at 280 nm and the absorbance of the dye at its maximum excitation wavelength, 
with the assumption that the molar extinction coefficient of the free dye and the conjugated 
dye remains the same. As we observed different absorbance properties of the free dye 
and the PA-Cy5 conjugated dye between 500 nm and 750 nm, we cannot assume the 
molar extinction coefficient remains the same in both samples. Thus, the degree of 
labelling, calculated to be ~4.5 molecules of dye per molecule of protein, is unlikely to be 
correct.  
 
Cyanine dyes are known to produce concentration dependent absorbance spectra as a 
result of dimerisation or H-aggregation (151,152). At low concentrations the absorbance of 
cyanine dyes results in a single maximum (151,152), as concentration increases the 
absorbance spectra presents a second maxima at a shorter wavelength due to dye 
aggregation (152). As the absorbance spectra of the PA-Cy5 conjugate is independent of 
concentration, it is likely that the close proximity of the dye molecules distributed on PA 
resulted in intramolecular dye-dye interactions.  
 
Unlike non-sulfonated Cy5 dye dimerisation that results in a total loss of fluorescence 
(153,154), the sulfonated analogue used here maintains a degree of fluorescence (153). 
Comparing the fluorescence of free Cy5 and PA-Cy5 demonstrates that the relationship 
between dye absorbance at 650 nm and fluorescence is approximately 10 fold lower for 
PA-Cy5 than free Cy5 dye. Trypsin digestion was used to identify the effect of degradation 
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on PA-Cy5 fluorescence over time. The digested PA-Cy5 increase in fluorescence over 
time, returning to free Cy5 levels of fluorescence after complete digestion. These results 
confirm that the presence of dye-dye interactions was the result of intramolecular 
proximity. The digestion of PA-Cy5 also resulted in the absorbance spectrum returning to a 
peak shape more characteristic of free Cy5. Using the digested PA-Cy5 to determine 
degree of labelling resulted in ~11.75 molecules of dye per molecule of protein, which is 
likely to be a more accurate estimation. 
Figure 2-14. Trypsin digestion of PA-Cy5 increases fluorescence and alters UV 
absorbance spectrum. 
The fluorescence of PA-Cy5 (squares) and free Cy5 dye (circles) was measured at five 
concentrations and plotted against absorbance at 650 nm (A). Standard curves were 
generated from the data to interpolate the relationship between dye absorbance and 
fluorescence. Three concentrations of PA-Cy5 were incubated with 1 µg of trypsin at 37°C, 
measuring the fluorescence (excitation 630 nm; emission 700 nm) at 1-minute intervals for 
60 minutes (B). PA-Cy5 fluorescence was measured prior to the addition of trypsin, pre – 
digestion, and 24 hours after the addition of trypsin, post – digestion, resulting in 
approximately 10-fold increase in fluorescence (C). PA-Cy5 UV absorbance spectrum 
before (black dashed) and 8 hours after the addition of trypsin (red solid) (D). 
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There are potential limitations to the high degree of labelling achieved here. Generally a 
high degree of labelling is considered detrimental due to potential alterations of protein 
surface charge (155), hydrophobicity (155), avidity (156), and function (156), as well as 
dye self-quenching effects (154). The modification of surface charge may alter in vivo 
biological activity, changing clearance mechanisms (155) or affecting immune recognition 
(157). While increasing the degree of labelling can result in a loss of function for antibodies 
(156), it is difficult to predict the effect of labelling proteins. Any effect will be highly specific 
to the combination of fluorescent dye and protein.   
 
The self-quenching observed for PA-Cy5 may be advantageous for a targeted imaging 
agent. As PA is internalised into cells and degraded its associated dye will increase in 
fluorescence while the intact protein that remains in circulation will have comparatively low 
fluorescence and subsequently reduce background signal. As tumours significantly 
upregulate expression of the anthrax toxin receptors (22-27), they will internalise more PA-
Cy5 than surrounding healthy tissues. Combined with the cell impermeability of the Cy5 
Figure 2-15. PA-Cy5 interacts with mouse squamous cell carcinoma cells in a dose 
dependent manner. 
HPV38E6E7 mouse SCC cells (~5 x 105) were incubated with PA-Cy5 for 30 minutes on 
ice, washed with PBS, and analysed by fluorescence activated cell sorting. Data was 
collected using an LSRFortessa X-20 cell analyser system and analysed using FlowJo 
software. The data presented is from the live cell population only, determined using 
Zombie Aqua live/dead stain. 
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dye, where the internalised dye will remain within the cell, the PA-Cy5 compound will result 
in substantially higher contrast between tumour and healthy tissue.  
 
As there are no solvent exposed amines located near the regions of PA responsible for 
receptor binding, dye conjugation is unlikely to affect receptor binding in solution. 
However, it is possible that the negatively charged dye may impede interactions with cell 
surface receptors due to membrane electrostatic interactions. Cell based binding studies 
are likely to provide a better indication of fluorophore effect compared to solution based 
binding kinetic analysis. Preliminary assessment of PA-Cy5 binding SCC cells was 
performed using flow cytometry, which demonstrated a concentration dependent 
association with SCC cells. Whilst all cells were positive for Cy5 at 300 nM PA-Cy5, 1200 
nM was not sufficient for receptor saturation demonstrated by a linear correlation between 
PA-Cy5 concentration and MFI.  
 
Overall, we demonstrated a method of E. coli recombinant expression and liquid 
chromatography-based purification of functional PA. Bioconjugation of the recombinant PA 
protein with an NHS functionalised Cy5 fluorescent dye resulted in ~11.75 molecules of 
dye per molecule of protein. Although the fluorescence of PA-Cy5 is approximately one 
tenth of free dye, digestion of the PA-Cy5 protein by trypsin demonstrated that when 
intermolecular dye-dye interactions are removed fluorescence returns to free Cy5 levels. 
Figure 2-16. Surface representation of PA highlighting solvent exposed amines. 
PA (PDB 4H2A) protein surface was generated using PyMOL molecular viewer software 
using a solvent radius of 1.4 Å. Each of the four domains is coloured a different shade of 
blue. Amines are highlighted in red, regions that interact with the anthrax toxin receptors 
are shown in yellow. 
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The PA-Cy5 demonstrated a concentration dependent interaction with mouse SCC cells, 
paving the way for further in vitro and in vivo studies identifying the potential of PA-Cy5 as 
an SCC targeting agent.  
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Chapter 3 – Protective Antigen shows high specificity for Tumour Endothelial 
Marker 8 Overexpression on Cutaneous Squamous Cell Carcinoma 
 
3.1 Introduction 
 
Non melanoma skin cancer (NMSC) has the highest incidence rate of all cancers, higher 
than all other cancers combined (158). Although NMSCs are not generally associated with 
high mortality, due to their extremely high incidence they represent a significant financial 
burden (159). Squamous Cell Carcinoma (SCC) accounts for approximately 20% of 
NMSCs but is responsible for the majority of NMSC related deaths due to potential 
metastatic spread if untreated (160), particularly in immunosuppressed persons (161,162) 
where organ transplant recipients have a 65-100 fold increase in SCC incidence compared 
to the general population (163). Identification of potential biomarkers of SCC that can be 
used for targeted therapies and rapid non-invasive diagnosis is needed, particularly for 
advanced and metastatic cases where current treatments fail (161). 
 
Protective Antigen (PA), a protein produced by B. anthracis, has been demonstrated to be 
a potential option for targeted delivery of drug molecules (76) or toxins (89) to tumours. PA 
is a component of the anthrax toxin, facilitating the translocation of toxin enzymes into the 
cytosol through highly specific and selective interactions with two highly conserved anthrax 
toxin receptors known as Tumour Endothelial Marker 8 (TEM8) and Capillary 
Morphogenesis Gene 2 (CMG2) (164). TEM8 and CMG2 are endothelial cell surface 
receptors involved in extracellular matrix (ECM) homeostasis (33,35) and angiogenesis 
(39,165) that exhibit differential expression in healthy and tumour tissues. TEM8 directly 
interacts with the actin cytoskeleton (166) and components of the ECM, such as collagen I 
(99) and α3 VI (98). The expression of TEM8 does not affect cell proliferation or 
differentiation (43), nor is it necessary during normal adult angiogenic events (34,39), but 
inhibition of TEM8 has been demonstrated to reduce tumour growth in mouse models (39).  
 
In patient derived samples of colorectal and gallbladder cancers, TEM8 expression 
increases with cancer grade and clinical staging (22,23), and has been associated with 
poor survival outcomes in breast cancer (26). CMG2 is involved in endothelial cell 
proliferation (165), adhesion (167), capillary formation in vitro (21), and collagen VI 
homeostasis in vivo (32). Expression of CMG2 has been inversely correlated to tumour 
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progression in breast cancer (29) and soft tissue sarcoma (30). As TEM8 and CMG2 share 
ligands they are likely to have overlapping or complementary functions in response to 
changes in the ECM. Additionally, human and mouse anthrax toxin receptors are 
extremely conserved, an advantageous property for translational research of a targeting 
agent. The expression of the anthrax toxin receptors in tumours may inform on 
pathological changes to the ECM involved in angiogenesis, invasiveness, and metastatic 
potential.  
 
Molecular imaging is an emerging non-invasive tool that can be used for the identification 
and prognostic assessment of cancers, as well as monitoring therapeutic delivery and 
effect (168). By targeting the anthrax toxin receptors, particularly TEM8, PA has significant 
potential as an imaging biomarker for tumour identification, monitoring, or targeted 
therapeutic drug delivery. However, despite PA targeted therapies showing promise in 
preclinical models, there is currently no data that confirms tumour specific localisation of 
PA in vivo.  
 
To determine whether PA can specifically target SCC tumours in vivo we recombinantly 
expressed PA and conjugated an amine reactive fluorescent dye for optical imaging of a 
HPV38E6E7-FVB transgenic mouse model. This model expresses oncogenes that 
interfere with cell survival pathways and promote cellular proliferation (169,170) producing 
SCC in response to repeated UV irradiation, a mechanism that is highly relevant to human 
SCC development.  
 
3.2 Methods 
 
3.2.1 Recombinant expression and purification of B. anthracis Protective Antigen 
 
BL21 E. coli was transformed with a pET-30b (+) plasmid containing a codon optimised 
Protective Antigen fusion protein with a C-terminal 12xHis tag preceded by a Tobacco 
Etch Virus cleavage sequence. The E. coli codon optimisation, gene synthesis, molecular 
cloning, and sequence validation was performed by the University of Queensland Protein 
Expression Facility. Lysogeny Broth media containing 50 µg/ml kanamycin was inoculated 
with the transformed E. coli and incubated at 37 °C, with shaking (250 RPM). When the 
OD600 reached ~2-3, the temperature was reduced to 22 °C. 1 mM isopropyl β-D-
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thiogalactopyranoside was added to the culture and incubated overnight with shaking. The 
cells were pelleted by centrifugation (10000 x g for 15 minutes) and resuspended in Nickel 
Binding Buffer (50 mM sodium phosphate, 300 mM NaCl, pH 8) containing 200 µg/ml 
lysozyme, 1 mM dithiothreitol, 5 % (w/v) glycerol, and 0.1 % (v/v) Triton. The cells were 
sonicated on ice for 20 minutes (5 seconds on, 10 seconds off) and centrifuged (40000 x g 
for 45 minutes). The supernatant was added to a pre-equilibrated 5 ml HisTrap FF column 
(GE life sciences). The column was washed with Nickel Binding Buffer containing 100 mM 
imidazole and eluted with Nickel Binding Buffer containing 250 mM imidazole. The 
imidazole was removed from the protein sample by buffer exchange using a 50K 
molecular weight cut-off Amicon Ultra-15 Centrifugal Filter (Merck). 1 mg of Tobacco Etch 
Virus protease and 1 mM Dithiothreitol was added to the PA protein and incubated at 4 °C 
for 24 - 48 hours. The cleaved protein was purified by reverse nickel affinity purification 
and the non-bound protein was buffer exchanged into 10 mM Tris, pH 8.0. The protein was 
added to a pre-equilibrated 5 ml DEAE anion exchange column (GE life sciences) and 
eluted with a 0-500 mM sodium chloride gradient over 200 ml. Fractions that contained the 
protein of interest were pooled and concentrated. Final purification of PA was performed 
by analytical size exclusion chromatography using a Superdex 200 Increase 10/300 GL 
column (GE life sciences).  
 
3.2.2 Fluorescent dye conjugation 
 
150 µg of sulfo-Cyanine5 (Cy5) NHS ester (Lumiprobe) was dissolved in 25 µL of dimethyl 
sulfoxide solution, and diluted to 100 µL with water. 900 µL of recombinant PA protein (2 
mg/ml) in 50 mM sodium phosphate buffer pH 8 was added to the dye solution, vortexed, 
and stored at 4°C overnight. The unreacted dye was removed using a 10K MWCO Amicon 
Ultra-4 Centrifugal Filter (Merck).  
 
3.2.3 Cell line 
 
The HPV38E6E7 SCC cell line, originating from tumours of UV-irradiated HPV38E6E7-
FVB mice, was generated in-house (171) and grown in a modified F12 medium 
supplemented with Dulbecco's Modified Eagle Medium and Fetal Bovine Serum (FBS) in a 
37 °C incubator containing 5 % CO2. 
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3.2.4 In vitro binding assay 
 
HPV38E6E7 SCC cells were plated onto poly-L-lysine coated coverslips and blocked 
using Roswell Park Memorial Institute medium containing 20 % FBS. Cells were incubated 
with PA-Cy5 (15 nM) in media at 37 °C for 30 minutes or at 4 °C for 30 minutes, washed 
with phosphate buffered saline (PBS) and incubated in fresh media at 37 °C for 30 
minutes. The blocking experiment was performed by incubating the cells with unlabelled 
PA (30 nM) in media on ice for 30 minutes, washed with PBS and incubated with PA-Cy5 
as described above. As a control, cells were incubated with free Cy5 dye (1 μM) in media 
on ice for 30 minutes, washed with PBS, and incubated in fresh media at 37 °C for 30 
minutes. After the final incubation, cells were washed with PBS, fixed in 4 % 
paraformaldehyde, and stained with 4′,6-diamidino-2-phenylindole (DAPI). Images were 
taken with a Nikon Ti/Spectral spinning disc confocal microscope, Plan Apo TIRF 60X Oil 
DIC H N2 objective, Andor Clara Dr-3222 camera, and NIS elements software. Integrated 
density of Cy5 fluorescence per cell was determined using maximum intensity projections 
of z-stacks using Image J FIJI software, cell boundaries were determined using cell 
autofluorescence.  
 
3.2.5 Optical imaging 
 
This study was carried out in accordance with the principles of the Basel Declaration and 
recommendations of Animal Care and Protection Act (2001) and the Australian code for 
the care and use of animals for scientific purposes (8th Edition). The protocol was 
approved by the University of Queensland Molecular Bioscience Animal Ethics Committee. 
An area of ~ 4 x 4 cm on the dorsal region of female HPV38E6E7-FVB mice was shaved 
periodically to remove fur. Sunblock was placed on the ears prior to irradiation to limit 
damage to ear skin. The awake animals were placed in a cage under a UV lamp and 
received a single exposure of UVB radiation three times a week starting at 120 mJ/cm2, 
gradually increased to 450 mJ/cm2 by day 140. UV dosing remained at 450 mJ/cm2 until 
characteristic squamous cell carcinoma was observed (170). Visual characteristics include 
but are not limited to the formation of wart like growths, elevated growth with a central 
depression, or open sores. Female HPV38E6E7-FVB mice of similar age without UV 
irradiation were used as controls. Three weeks after the final UV treatment 75 μg of PA-
Cy5 in PBS was administered intravenously via the tail vein and imaged using a Bruker 
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Carestream In Vivo MS FX Pro. In vivo images were taken prior to injection, 8, 24, and 48 
hours post injection. Animals were anaesthetised with 3-5 % isoflurane and allowed to 
recover at each imaging time point. The mice were sacrificed 48 hours post injection, and 
the major organs were removed for ex vivo imaging. Fluorescence images were obtained 
using 7 excitation wavelengths (550, 570, 590, 600, 610, 620, and 630 nm), 10 seconds 
exposure, aperture (f stop) 2.8, field of view 190 mm2, 2 x 2 bins, 700 nm emission filter. 
Reflectance (white light) images were obtained using 450 nm excitation wavelength, 0.5 
seconds exposure, aperture (f stop) 7.46 field of view 190 mm, 1 x 1 binning, unfiltered 
emission. X-ray images were obtained with 10 seconds exposure, aperture (f stop) 2.8, 
field of view 190 mm, and 2 x 2 binning.  
 
3.2.6 Histology and immunofluorescence 
 
Skin tissue was fixed in 10 % neutral buffered formalin, paraffin embedded and sectioned 
(5 μm). Haematoxylin and eosin stained sections were imaged using a Nikon Eclipse Ti 
microscope, Plan Fluor ELWD 20X DIC L objective, DS-Fi2-U3 camera, and NIS elements 
software. Immunofluorescence antigen retrieval was performed in citrate buffer pH 6, 
boiling for 2 minutes and allowing to cool to room temperature. The sections were blocked 
with 2 % bovine serum albumin in PBS for 30 minutes at room temperature. Polyclonal 
rabbit anti-TEM8 (ab19387) and polyclonal goat anti-CMG2 (ab101711) were diluted 1:500 
and incubated on the tissue overnight at 4 °C. The sections were washed with PBS and 
incubated with anti-rabbit CF488 (Sigma) and anti-goat CF555 (Sigma) secondary 
antibodies for 30 minutes at room temperature. The sections were then washed with PBS 
and stained with DAPI. Immunofluorescence images were taken using an Olympus 
FV1200 confocal microscope, UPLSAPO20X objective, photomultiplier tube detector, and 
FV10 software. 
 
3.2.7 Colocalisation analysis 
 
Quantification of fluorescence colocalisation by Pearson’s correlation coefficient (172) and 
intensity correlation quotient (173) was determined using ImageJ software (174,175). 
Immunofluorescence images from 6 randomly selected sites within an SCC tumour were 
used for analysis. For each of the immunofluorescence images, a region containing no 
tissue was used to perform a background subtraction prior to analysis. 
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3.2.8 Ex vivo flow cytometry 
 
Tumour and skin sections were harvested from animals, scraped to remove subcutaneous 
fat, and place in 1 mL of digestion media (RPMI media, 2% fetal bovine serum, 3mg/mL 
collagenase D, 5 µg/ml DNAse I). The tissue samples were cut into fine pieces using 
surgical scissors. The samples were incubated at 37°C for ~70 minutes, mixed every 30 
minutes. The samples were strained through 70 µm cell strainers and washed twice with 
FACS buffer (PBS containing 10% FCS). Zombie Aqua (Biolegend) dye was used for 
determination of live/dead cell populations as per the manufacturer’s instructions. Flow 
cytometry was performed using an LSRFortessa X-20 cell analyser system (BD 
Biosciecnes) and data analysed using FlowJo software (Tree Star Inc.). 
 
3.2.9 Statistical analysis 
 
All statistical analysis was performed using GraphPad Prism software. Integrated density 
of in vitro internalisation was analysed using two tailed unpaired T test with Welch's 
correction. Mean relative fluorescence intensity between the tumour and major organs 
within the UV+ group (n = 5) was analysed using an ordinary One-Way ANOVA with 
Tukey’s multiple comparisons test. Mean fluorescence intensity of the major organs 
between the UV+ (n = 5) and UV− (n = 6) groups was analysed using an ordinary Two-Way 
ANOVA with Sidak’s multiple comparisons test. Statistical analysis of ex vivo flow 
cytometry was performed using an ordinary Two-Way ANOVA with Tukey’s multiple 
comparisons test. 
 
3.3 Results 
 
3.3.1 Fluorescently labelled PA maintains cell binding and internalisation in vitro 
 
We first confirmed that the amine bioconjuagted PA maintained binding and translocation 
into SCC cells. PA-Cy5 was incubated with cells at 4 °C to saturate the available receptors 
and minimise cellular metabolism and receptor internalisation (Fig. 3-1A). Unbound PA-
Cy5 was removed and the cells were incubated at 37 °C to restore cell metabolism. 
Abundant fluorescence uptake was observed in the cells, with characteristic focal points of 
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internalisation. To confirm that the internalisation of PA-Cy5 was a receptor mediated 
process, a blocking experiment was performed where the cells were pre-treated with 
unlabelled PA. Blocking the available receptors prior to incubation with PA-Cy5 resulted in 
a significant reduction of fluorescence (p < 0.0001, two tailed unpaired T test), determined 
by analysing the integrated density per cell (Fig. 3-1B).  
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The minimal fluorescence uptake observed in the 4 ºC PA block experiment was likely due 
to displacement of the unlabelled PA during PA-Cy5 incubation or natural oligomerisation 
of PA/PA-Cy5 molecules. Continuous uptake of PA-Cy5 at 37 ºC resulted in greater 
distribution throughout the cells and more defined cell boundaries (Fig. 3-1C). Again, 
blocking the available receptors prior to incubation with PA-Cy5 reduced the observable 
fluorescence resulting in a significant reduction (p < 0.0001, two tailed unpaired T test) in 
integrated density per cell  (Fig. 3-1D). A control experiment was performed by incubating 
the cells with free Cy5 dye to determine non-specific binding or internalisation due to the 
dye molecule, the low fluorescence uptake observed was likely due to pinocytosis.  
 
3.3.2 PA is highly specific to cutaneous SCC in vivo 
 
UV+ tumour bearing mice (Fig. 3-2A-E) and UV− naïve controls (Fig. 3-2F-J), were 
administered 75 µg fluorescent PA-Cy5 via the tail vein and optically imaged at several 
time points over 48 hours. Imaging was performed 3 weeks after the final UV treatment to 
minimise any effects of UV induced inflammation. Fluorescence images were obtained 
using an excitation wavelength of 630 nm and emission wavelength of 700 nm as these 
were the optimal settings for visualisation of Cy5 (Fig. 3-3A). Fluorescence was localised 
to the regions which displayed SCC characteristics on the dorsal region and ears of UV+ 
mice, while no specific localisation was visible in the UV− mice.  
Figure 3-1. Fluorescently labelled PA maintains cell binding and internalisation in 
vitro. 
Cells were plated on glass cover slips coated with poly-L lysine at 105 cells/coverslip 18 
hours before staining. Cells were incubated with PA at 4 °C to saturate the available 
receptor sites prior to internalisation (A) or at 37 °C for continuous cell uptake (C). 
Blocking experiments (PA Block) were performed by incubating the cells with unlabelled 
PA on ice prior to the addition of PA-Cy5. Cells were washed with PBS before fixation in 4 
% paraformaldehyde. Analysis of integrated density of Cy5 fluorescence per cell, 
visualised with box-and-whisker plots, identified PA-Cy5 internalisation into SCC cells was 
significantly reduced by blocking the available receptor sites with unlabelled PA at 4 °C (B) 
and 37 °C (D). Cyan, DAPI nuclear stain; magenta Cy5. Scale bar represents 20 µm. 
Statistical analysis performed using two tailed unpaired T test with Welch's correction (* p 
= 0.0495, **** p < 0.0001). 
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To better visualise PA-Cy5 fluorescence, spectral unmixing was performed using Bruker 
Multispectral software. Images were obtained at every time point using seven excitation 
wavelengths (550, 570, 590, 600, 610, 620, and 630 nm) measuring the emission of each 
excitation at 700 nm. Spectral profiles were modelled for fur and PA-Cy5 fluorescence. 
The models were applied to all time points, separating the raw fluorescence signal into 
either fur or PA-Cy5 channels (Fig. 3-3B). PA-Cy5 fluorescence correlates to the region of 
peak intensity observable in the initial fluorescence images. Unmixed images confirmed 
PA-Cy5 fluorescence localised to the tumour regions at 8 hours post injection with lower 
fluorescence observable in the skin surrounding the tumour, consistent with the distribution 
of fluorescence seen in the 630 nm optical image. At 24 and 48 hours post injection the 
PA-Cy5 fluorescence is highly specific to the tumour regions with no detectable signal in 
the tumour adjacent skin or control animals.  
 
Figure 3-2. Images of HPV38E6E7-FVB mice. 
UV+ SCC tumour bearing mice (A-E) and UV− naïve controls (F-J). Black arrows highlight 
regions associated with tumour growth on the ears and dorsal region of UV+ animals. 
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3.3.3 PA-Cy5 demonstrates low uptake in healthy skin and organs 
 
Optical imaging was performed on the dissected mouse organs 48 hours post injection of 
PA-Cy5 to identify fluorescence localisation to the tumour and organs (Fig. 3-4). The 
highest relative fluorescence intensity (RFI) was observable at the tumour and in the 
gastrointestinal (GI) tract. The majority of fluorescence observed in the GI tract is a result 
of the animal feed, images acquired from organs of UV− mice that did not receive PA-Cy5 
resulted in similar mean RFI of the GI tract as in the PA-Cy5 administered mice. The 
fluorescence of the tumour corresponds to the skin abnormalities visible in the reflectance 
(white light) image and increased tissue density in the X-ray image. Fluorescence was also 
present in the liver, kidneys, and lungs at lower intensities. 
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3.3.4 PA-Cy5 tumour uptake is significantly higher than healthy tissues 
 
Peak RFI was observed 8 hours post injection, where mean RFI of the tumours was 
approximately three times higher than adjacent skin and control animals. Rapid clearance 
of fluorescence from non-tumour regions was observed. Twenty four hours post injection 
the control animals returned to pre-injection baseline, while the tumour bearing animals 
retained fluorescence exclusively at the tumour regions. The tumour localised 
fluorescence decreased over the imaging experiment, decaying exponentially at a rate of 
~7 % mean RFI per hour (Fig. 3-5A), and remained detectable 48 hours post injection. The 
mean RFI of the tumour region was significantly different compared to the blood, heart, 
spleen, lungs, kidneys, liver, and skin (p < 0.0001, One-Way ANOVA) of the UV+ group, 
but not significantly different compared to the GI tract (p 0.064, One-Way ANOVA). The 
mean RFI of tumours was approximately three times higher than the liver and four times 
higher than the kidneys (Fig. 3-5B). Organ fluorescence was comparable between the UV+ 
and UV− groups administered PA-Cy5 with no statistically significant variance between the 
Figure 3-3. PA-Cy5 is highly specific to cutaneous SCC in vivo. 
Two groups of HPV38E6E7-FVB mice were imaged prior to injection, 8, 24, and 48 hours 
post injection of 75 µg PA-Cy5 via tail vein. The UV+ group has developed squamous cell 
carcinomas on their back. The UV− group is of a similar age to the UV+ group but have 
not been exposed to UV irradiation. Fluorescent in vivo optical images of PA-Cy5 using 
630 nm excitation/700 nm emission (A). Localisation of PA-Cy5 to the SCC tumours is 
observed reaching peak relative fluorescence intensity (RFI) ~8 hours post injection. 
Exclusive detection of tumours can be observed by 24 hours post injection, where control 
animals reach background levels of fluorescence. Spectrally unmixed in vivo optical 
images (B). A series of images were taken at each time point using multiple excitation 
wavelengths, measuring the emission at 700 nm. Optical spectra were modelled for fur 
auto-fluorescence and PA-Cy5 fluorescence using Bruker Multispectral software. These 
models were applied to the images, isolating the signal from the fur (cyan) and PA-Cy5 
(magenta), demonstrating the tumour specific localisation of PA-Cy5. Fluorescence arising 
from PA-Cy5 is undetectable in the skin 24 hours post injection, but remains localised to 
the tumour 48 hours post injection. The calibration bars represent relative fluorescence 
intensity (RFI). Fluorescence data is overlayed on reflectance (white light) images. 
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mean intensity of the blood, heart, spleen, lungs, kidneys, liver, or skin (p > 0.915, Two-
Way ANOVA).  
 
3.3.5 UV irradiated skin sections show characteristics of SCC 
 
Haematoxylin and eosin staining of formalin-fixed paraffin-embedded UV+ and UV− skin 
samples showed significant differences associated with the development of SCC (Fig. 3-
6). UV+ tumour skin showed hyperkeratosis and parakeratosis characterised by the 
thickening of the stratum corneum, the outermost layer of the epidermis, and retention of 
nuclei in the stratum corneum respectively. Epidermal hyperplasia and atypical crowding of 
keratinocytes was visible in the UV+ skin as well as budding of the basal layer of the 
epidermis into the dermis. Solar elastosis, increased vascularisation, immune filtration, 
dense nucleation of the dermis, and invasion into the subcutaneous fat was also present in 
the UV+ skin.  
 
3.3.6 PA-Cy5 colocalises with the overexpression of TEM8 in SCC 
 
Figure 3-4. PA-Cy5 demonstrates low uptake in healthy skin and organs. 
UV+ tumour bearing and UV− control mice were euthanised 48 hours post injection of PA-
Cy5. The major organs from each animal were optically imaged using 630 nm excitation 
and 700 nm emission. Organs were also imaged from UV− control mice that were not 
administered PA-Cy5 (UV− no PA) for autofluorescence comparison. 1. Blood, 2. Heart, 3. 
Lungs, 4. Spleen, 5. GI tract, 6. Liver, 7. Kidneys, and 8. Dorsal skin. A white arrow 
indicates the tumour region. Calibration bar represents relative fluorescence intensity 
(RFI). Fluorescence data is overlayed on X-ray images. 
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Anti-TEM8 and anti-CMG2 antibodies were used to visualise the expression of the anthrax 
toxin receptors in formalin-fixed paraffin-embedded mouse skin tissue (Fig. 3-7). TEM8 
expression was significantly upregulated throughout the UV+ skin, localised to the 
nucleated stratum corneum and dermal regions. No detectable expression of TEM8 was 
visible in the UV− control skin. CMG2 was also upregulated in the UV+ skin compared to 
UV− skin, with the highest expression localised to the thickened epidermis and basal 
budding structures. Lower expression of CMG2 was observed in the UV− skin localised to 
the epidermis and sebaceous glands. Both TEM8 and CMG2 secondary antibody controls 
showed non-specific binding that appears localised to vessel structures.  
 
Figure 3-5. PA-Cy5 tumour uptake is significantly higher than healthy tissues. 
Tumour, fur, and skin regions of interest were identified to determine mean RFI for UV+ 
HPV38E6E7-FVB tumour bearing mice (n=5) and UV− HPV38E6E7-FVB control mice 
(n=6). The mean RFI is plotted against time, with an exponential decay curve fit to the 
tumour data (solid line). Regions of interest were identified using reflectance images (white 
light) to prevent fluorescence bias. Error bars represent the standard deviations of the 
mean (A). 48 hours after the injection of PA-Cy5 the animals were sacrificed, tumours and 
organs were removed and optically imaged. Columns represent the mean RFI for UV+ and 
UV− samples and the error bars are the standard deviations. One-Way ANOVA analysis 
resulted in significant differences (P < 0.0001) between the tumour and blood, heart, 
lungs, spleen, kidneys, liver, and skin of the UV+ group. Two-way ANOVA analysis 
resulted in no statistically significant differences between the UV+ and UV− groups blood, 
heart, lungs, spleen, GI tract, kidneys, liver, or skin fluorescence (B). 
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PA-Cy5, administered to the animals via tail vein 48 hours prior to culling, was present in 
the UV+ skin but not the UV− skin consistent with the optical imaging experiments. PA-Cy5 
was highly colocalised with TEM8 expression but was not detectable in the regions with 
the highest CMG2 expression. Colocalisation analysis was performed on 6 randomly 
selected regions of an SCC tumour (Table 3-1), quantified using Pearson’s correlation 
coefficient (PCC) and intensity correlation quotient (ICQ). PCC is a measure of linear 
relationship between pixel signal co-occurrence and intensity resulting in a value from -1 
(perfect negative correlation) to +1 (perfect positive correlation), with distributions that are 
uncorrelated resulting in values near zero (176). ICQ is a measure of correlation based on 
the ratio of pixel intensity synchronicity between two channels with respect to mean image 
intensities resulting in a value from – 0.5 (perfect exclusive) to + 0.5 (perfect 
colocalisation), where values near zero represent random staining (173). Across all 
samples tested, the correlation between TEM8 and PA-Cy5 is consistently higher than 
CMG2 and PA-Cy5 for both PCC and ICQ methods.  
 
3.3.7 Ex vivo flow cytometry of skin tissue demonstrated cell associated fluorescence 
 
Tumour and non-tumour associated sections of skin were removed, digested, and 
analysed using flow cytometry for Cy5 fluorescence. Dorsal skin that was exposed to UV 
irradiation but did not have visual characteristics of SCC and ventral skin that did not 
receive UV irradiation were used as controls, referred to as UV+ skin and UV− skin 
respectively. In general the tumour tissue resulted in a higher percentage of cells positive 
Table 3-1. Colocalisation quantification of an intravenously injected PA-Cy5 with 
its receptors in an SCC tumour. 
Sample Pearson's Correlation Coefficient Intensity Correlation Quotient TEM8 & PA-Cy5 CMG2 & PA-Cy5 TEM8 & PA-Cy5 CMG2 & PA-Cy5 
1 0.389 0.077 0.117 0.069 
2 0.651 0.276 0.253 0.17 
3 0.555 0.239 0.202 0.155 
4 0.663 0.355 0.29 0.222 
5 0.708 0.292 0.288 0.175 
6 0.648 0.141 0.25 0.123 
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for Cy5 (Fig. 3-8A) and median fluorescence intensity (MFI) (Fig. 3-8B) compared to 
controls tissues. Both percentage positive and MFI values demonstrated high variability 
between individual animals. Statistical analysis of tumour versus appropriate non-tumour 
tissues for each mouse demonstrate a general trend of highly significant differences (Table 
3-2). 
 
3.4 Discussion 
 
Optical imaging is a potential cost effective means of screening superficial tumours in 
preclinical models (177). Optical probes that target skin cancers could have significant 
benefit in skin cancer screening, improving tumour detection and reducing costs. We have 
identified that PA, a protein produced by B. anthracis, conjugated to a fluorescent dye is 
highly specific to HPV positive UV induced mouse SCC. Although there is overexpression 
of both anthrax toxin receptors, the administered PA-Cy5 is primarily colocalised with 
TEM8.  
 
Table 3-2. Statistical analysis of ex vivo flow cytometry. 
Mouse Comparison % cell Cy5 positive MFI 
1 
Ear Tumour vs. Ear Control <0.0001 <0.0001 
Dorsal Tumour vs. UV+ Skin 0.0007 <0.0001 
Dorsal Tumour vs. UV- Skin <0.0001 <0.0001 
2 
Ear Tumour vs. Ear Control <0.0001 <0.0001 
Dorsal Tumour vs. UV+ Skin <0.0001 <0.0001 
Dorsal Tumour vs. UV- Skin <0.0001 <0.0001 
3 
Ear Tumour vs. Ear Control <0.0001 <0.0001 
Dorsal Tumour vs. UV+ Skin <0.0001 <0.0001 
Dorsal Tumour vs. UV- Skin <0.0001 <0.0001 
4 
Ear Tumour vs. Ear Control <0.0001 <0.0001 
Dorsal Tumour vs. UV+ Skin <0.0001 <0.0001 
Dorsal Tumour vs. UV- Skin 0.1051 0.002 
5 
Ear Tumour vs. Ear Control 0.5333 0.7118 
Dorsal Tumour vs. UV+ Skin <0.0001 0.0002 
Dorsal Tumour vs. UV- Skin <0.0001 <0.0001 
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Amine bioconjugation is a common technique for labelling proteins of interest with imaging 
molecules. A limitation of non-specifically labelling PA with an amine reactive cyanine dye 
is that we were unable to spectrally quantify the degree of labelling. A known occurrence 
with cyanine dyes is their propensity to form aggregates when in close proximity, resulting 
in a homo-FRET self-quenching effect (154). By using the sulfonated analogue of Cy5 we 
avoid the homo-fret self-quenching (153,154), but due to a high degree of labelling there is 
a non-linear relationship between degree of labelling and spectral properties. For the 
purposes of assessing the localisation of PA-Cy5 to SCC tumours the degree of labelling 
is inconsequential, provided that PA-Cy5 maintains its ability to bind and internalise into 
cells.  
 
As there is potential to disrupt protein stability or binding affinity by non-specifically 
modifying amines, we first confirmed that the PA-Cy5 protein maintained cell binding and 
internalisation in vitro. Receptor specific uptake of PA-Cy5 into SCC cells was observed, 
which was drastically reduced by pre-incubation with unlabelled PA, demonstrating that 
non-specific modification of PA amines does not prevent receptor binding or 
internalisation. Receptor specific uptake of PA-Cy5 into SCC cells was observed, which 
was drastically reduced by pre-incubation with unlabelled PA, demonstrating that non-
specific modification of PA amines does not prevent receptor binding or internalisation. By 
reducing the temperature cellular metabolism and receptor turnover is reduced (178). 
Incubated the cells at 4 °C with PA-Cy5 and removing unbound protein before increasing 
Figure 3-6. UV irradiated mouse skin sections show characteristics of human SCC. 
Representative haematoxylin and eosin (H&E) stained sections from an SCC tumour (A) 
and dorsal skin from a UV− naïve control mouse (B). HK. Hyperkeratosis. E. Epidermis. D. 
Dermis. SF. Subcutaneous fat. Arrows highlight sebaceous glands. Scale bar 100 μm. 
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the temperature demonstrates that PA-Cy5 is associated with the cells. Subsequent 
internalisation of PA-Cy5 was identified by focal points of fluorescence within the cell. As 
we do not see a clear delineation of the cell membrane it is likely that the PA-Cy5 
association is due to receptor binding, and is not a result of non-specific cell membrane 
association. Pre-incubation with unlabelled PA significantly reduces the cellular uptake of 
fluorescence (p<0.0001, two tailed unpaired T test with Welch's correction), further 
demonstrating a receptor specific interaction between PA-Cy5 and the SCC cells. 
Continuous internalisation of PA-Cy5 at 37 °C demonstrated internalised fluorescence as 
well as defined cell surfaces, indicating cell surface associated PA-Cy5 at the time of 
fixation. Pre-incubation with unlabelled PA again significantly reduces the cellular uptake 
of fluorescence (p<0.0001, two tailed unpaired T test with Welch's correction).  
 
Figure 3-7. PA-Cy5 colocalises with the overexpression of TEM8 in SCC. 
Skin samples were taken from tumour bearing mice (UV+) and control mice (UV−) 48 hours 
after PA-Cy5 injection. Formalin-fixed paraffin-embedded skin samples were stained for 
the presence of the anthrax toxin receptors TEM8 and CMG2 using antibodies. TEM8 was 
significantly overexpressed in tumour tissue compared to UV− control, colocalised with the 
in vivo administered PA-Cy5. CMG2 was also significantly overexpressed in tumour tissue, 
with detectable expression in the UV− control skin epidermis and sebaceous glands. 
Secondary antibody controls were performed using UV+ skin tissue. DAPI, cyan, 405 nm; 
TEM8, red, 488 nm; CMG2, yellow, 555 nm; PA-Cy5, magenta, 630 nm. Primary 
antibodies were incubated on the tissue for 1 hour at room temperature; secondary 
antibodies for 30 minutes at room temperature. Scale bar represents 100 μm. 
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The fluorescence observed in the PA blocking experiments may be due to several factors. 
Firstly, at 4 °C  the cells have reduced metabolism, but some degree of receptor recycling 
still occurs (178). This may be enhanced by PA activated receptor internalisation (45) and 
an equilibrium between surfaced exposed receptors and intracellular receptors (42). 
Secondly, as PA is able to form complexes with itself (138) PA-Cy5 may associate with 
unlabelled PA bound to receptors. In order to form these complexes PA requires 
enzymatic cleavage (179), which would also occur at a reduced rate due to the low 
temperature, and therefore would limit the effect. It is important to note that it is unknown 
whether the amine modification has disrupted this aspect of PA. Thirdly, the binding of PA-
Cy5 is occurring in a dynamic system. Although the available receptors may be initially 
occupied by unlabelled PA, in the presence of excess PA-Cy5 there may be some 
Figure 3-8. Ex vivo flow cytometry of skin tissue demonstrated cell associated 
fluorescence. 
Skin samples were taken from various regions of HPV38E6E7-FVB mice bearing SCC 
tumours 48 hours post injection of PA-Cy5. The samples were digested and isolated cells 
analysed by flow cytometry for Cy5 fluorescence. UV+ skin represents non tumour 
associated dorsal skin that received UV exposure, UV− skin represents skin taken from the 
ventral region that was not exposed to UV irradiation. Each bar represents an individual 
animal, mean values of triplicate samples with standard deviation error bars. Data was 
collected using an LSRFortessa X-20 cell analyser system and analysed using FlowJo 
software. The data presented is from the live cell population determined using Zombie 
Aqua live/dead stain. 
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dissociation of unlabelled PA allowing for the association of PA-Cy5. As the sulfonated 
analogue of Cy5 used here is cell impermeable due to its anionic charge (180), the free 
Cy5 experiment demonstrates that there is negligible dye uptake by the SCC cells through 
nonspecific internalisation. This experiment further validates that the cellular uptake of 
fluorescence is a direct result of PA and its receptor specific internalisation.  
 
PA-Cy5 administered via tail vein resulted in rapid tumour uptake, reaching maximum 
tumour intensity 8 hours post injection and tumour specific localisation by 24 hours. The 
time scale of PA-Cy5 tumour uptake and clearance observed here is significantly longer 
than the clearance reported in the literature for wild type PA (92). The increase in 
circulation time may be due to reduced proteolysis caused by steric hindrance of protease 
recognition sites, or changes in protein electrostatic and hydrophobic properties as a result 
of dye conjugation. The highly specific and prolonged retention of the intravenously 
administered PA-Cy5 to the SCC tumours, on both the dorsal skin and ears, allows for a 
practical imaging time window that may translate clinically. Light scattering, light 
attenuation, and autofluorescence are potential limitations of fluorescence optical imaging. 
This model of SCC is extremely well suited to optical studies due to the shallow tumour 
depth, limiting any effect of light scattering and attenuation. Additionally, the similarity in 
tumour development between this model and human cutaneous SCC could improve 
clinical translation. While the spectral unmixing can be used to better visualise specific 
fluorophores from endogenous signals and autofluorescence, using near infra-red 
fluorophores that are excited by longer wavelengths would also improve visualisation 
(181). 
 
Ex vivo imaging was used to obtain semi-quantitative data on the biodistribution of 
fluorescence within the major mouse organs. Forty-eight hours post injection, relatively low 
fluorescence intensity was observed in the lungs, kidneys, liver, and healthy skin. 
Significantly higher fluorescence intensity was observed in the GI tract and tumour. Whilst 
the majority of fluorescence within the GI tract can be attributed to the mouse feed (182), 
the significant localisation of fluorescence to the tumour suggests specific upregulation of 
the anthrax toxin receptors. Although TEM8 has been suggested to be highly expressed in 
the epithelial cells of the skin, lungs, and intestine (91), our results demonstrate the natural 
expression of the anthrax toxin receptors in healthy tissues results in significantly lower 
uptake of PA-Cy5 compared to tumour regions.  
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We identified that both anthrax toxin receptors are overexpressed in the UV+ skin 
associated with SCC relative to the UV− naïve control. Interestingly, TEM8 and CMG2 are 
expressed in different cellular structures within the skin. TEM8 expression was localised to 
the nucleated stratum corneum and dermis, whereas CMG2 expression was primarily 
localised to the thickened epidermis including basal budding structures but also present at 
lower levels throughout the dermis. In the UV− skin TEM8 was undetectable, whereas 
CMG2 expression was detectable selectively in the epidermis and sebaceous glands. To 
date there is limited information about the tissue distribution of TEM8 and CMG2. 
Published immunofluorescence of CMG2 expression in healthy mouse skin resulted in 
highly similar distribution (165), confirming our results. The TEM8 expression we 
observed, however, does not support published results that describe localisation to the 
keratinocytes (epidermis) and follicular cells of healthy mouse skin (91). Interestingly, the 
previously reported TEM8 expression patterns are highly similar to the CMG2 expression 
observed here. It is possible that the polyclonal antibody used for the previous 
immunohistochemistry study inadvertently cross reacted with CMG2. As we are the first to 
co-stain for both receptors we can be confident that the observed distribution presented 
here is attributed to the individual anthrax toxin receptors.  
 
The expression pattern of the anthrax toxin receptors is consistent with the localisation of 
their endogenous ligands. TEM8 was previously identified to interact with collagen I (99) 
and collagen α3 VI (98). Collagen I is the most abundant collagen subtype of the ECM and 
is the major component of the dermal interstitial matrix, collagen α3 VI is similarly located 
in the interstitial matrix (183). CMG2 is known to bind laminin, collagen IV (21) and 
collagen VI (32). Laminin and collagen IV are ECM components primarily located in the 
basal lamina and basement membrane anchoring cells to connective tissue (183), such as 
the epidermis to the dermis. Although the function of the anthrax toxin receptors during 
tumour development is still unknown, ECM interactions are important in many cellular 
functions that drive tumour development, invasion, and metastatic progression (6). The 
anthrax toxin receptors may inform on tumour specific ECM changes providing valuable 
information on disease progression and metastatic potential. 
 
The intravenously injected PA-Cy5 was highly colocalised with TEM8 but not present in 
the regions of the highest CMG2 expression. The reason for selectivity to TEM8 in this 
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case is unknown. CMG2 has been described as the primary receptor for the anthrax toxins 
due to higher PA affinity (70). In vivo it is possible that TEM8 may be more accessible than 
CMG2 from an intravenous injection. Immunofluorescence demonstrates that TEM8 is 
generally expressed within the dermis, while CMG2 is present in both dermal and 
epidermal regions. As the majority of skin microvasculature is located within the dermis 
(184), receptors expressed in this region are more accessible to an intravenously 
administered agent. The thickened epidermis likely suffers from low or no blood flow, as a 
result the administered PA-Cy5 is unable to reach the epidermal regions despite significant 
expression of CMG2. In addition the available CMG2 receptors in the epidermal regions 
may also be occupied by endogenous ligands preventing PA interaction.  
 
Quantification of colocalisation consistently demonstrated greater colocalisation of the 
intravenously administered PA-Cy5 with TEM8 expression compared to CMG2 expression. 
It is important to note that due to the dependence on a linear relationship the Pearson’s 
correlation coefficient is affected by the heterogeneity of receptor expression and PA-Cy5 
uptake within the tissue, as a result the values determined are under-representative of the 
degree of correlation (176). Similarly, ICQ is also under-represented in this data. As ICQ is 
a measure of the ratio of pixel intensity synchronicity between the receptor and PA-Cy5, 
there will always be asynchronicity as a result of PA-Cy5 binding to two receptors. Despite 
these limitations, the PCC and ICQ values can still be directly compared within each 
sample and consistently demonstrates that there is a higher degree of correlation between 
TEM8 and PA-Cy5 relative to CMG2 and PA-Cy5.  
 
Flow cytometry of digested tissues demonstrated significantly higher fluorescence in 
tumour associated skin tissue versus non-tumour associated skin tissues 48 hours post 
injection of PA-Cy5. A potential cause of variability in the flow cytometry results is due to 
difficulty in defining regions that contain cancer cells. Due to the heterogeneous nature of 
tumour development there is no defined region that only consists of cancer cells. It is likely 
that each individual tumour has a different mix of cancer and healthy cells, which would 
affect the flow cytometry results. It is possible that flow cytometry could be used to isolate 
and characterise the cells that contain PA-Cy5, determining the specific cell types that 
over express the anthrax toxin receptors during SCC development. Repeating this 
experiment at an earlier time point after injection would likely result in higher fluorescence 
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intensities, and provide more information of the relative uptake in SCC cells compared to 
normal healthy skin cells. 
 
The specific localisation and prolonged retention of PA-Cy5 to tumours is likely due to the 
mechanism of receptor internalisation. TEM8 is regulated by an endocytic transport 
mechanism, where there is an equilibrium between surface and cytosolic TEM8 (42). This 
pool of available unoccupied receptors residing in the endosomal recycling pathway allows 
rapid PA uptake by continually replacing surface receptors (42). PA is also able to activate 
receptor clustering (44) and endocytosis (45) similar to endogenous ligands, in addition to 
forming heptameric or octameric complexes (185), further enhancing cellular uptake. 
Healthy cells that have relatively low or undetectable levels of TEM8 on their surface will 
be unable to internalise PA at the same rate, providing the necessary contrast for tumour 
detection. The cell surface expression, recycling mechanism, as well as the potential role 
in ECM remodelling and invasion, highlight TEM8 as a novel biomarker of cutaneous SCC 
for targeted imaging. While the oligomerisation and active internalisation of PA is a unique 
advantage over antibody or peptide based targeted agents for rapid and selective tumour 
uptake. 
 
Overall we have shown that intravenously injected recombinant B. anthracis PA labelled 
with a near infrared fluorophore is highly specific to a physiologically relevant mouse 
model of cutaneous SCC. Whilst there is overexpression of both anthrax toxin receptors, 
TEM8 appears to have a more significant role in the uptake of the intravenously 
administered PA-Cy5. As TEM8 is extremely conserved between humans and mice, there 
is potential for direct translation. Based on these results, PA is a highly specific agent for 
targeting tumours overexpressing the anthrax toxin receptors, such as cutaneous SCC, 
and may have future diagnostic or therapeutic applications as a systemic targeting agent.  
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Chapter 4 – PET/CT Analysis and Biodistribution of 89Zr labelled PA 
 
4.1 Introduction 
 
Squamous cell carcinoma (SCC) is an extremely common non-melanoma skin cancer that 
has increasing incidence and financial burden (186). Although SCC accounts for 
approximately 20% of non-melanoma skin cancers in the USA (187) and 30% in Australia 
(188), it is responsible for the majority of NMSC related deaths due to a greater risk of 
metastatic spread (160,161). SCC is particularly prevalent in organ transplant patients as a 
result of immunosuppression (162), with an incidence 65-100 fold higher than the general 
population (163). Biomarkers of SCC that could be targeted by a systemically administered 
agent could provide a means of rapid tumour identification. A potential avenue of tumour 
identification is targeting biomarkers that inform on pathological changes to the 
extracellular matrix (ECM) as a result of tumour development, progression, and 
metastasis. 
 
The ECM is highly important in all cellular functions, providing structural support for tissues 
as well as regulating cellular proliferation, differentiation, survival, motility, vascular 
development, and immune functions, through biochemical and biophysical cell signalling 
(5). Disruption of the complex regulation of the ECM results in many diseases including 
cancer (5). The ECM has been suggested to influence the various hallmarks of cancer, 
sustaining proliferative signalling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, 
avoiding immune destruction, deregulating cellular energetics, enabling genomic mutation 
and instability, and enabling tumour promoting inflammation (6). The anthrax toxin 
receptors, Tumour Endothelial Marker 8 (TEM8) and Capillary Morphogenesis Gene 2 
(CMG2), are potential links between the ECM and tumour development and progression. 
TEM8 and CMG2 are highly conserved transmembrane proteins (189) that function in 
aspects of cell motility and adhesion (43,167,190), ECM homeostasis (32,33,35), and 
angiogenesis (21,39,189) through interactions with the ECM components collagen I, IV, VI, 
and laminin. The anthrax toxin receptors have several key features that are considered to 
be important characteristics for targetable biomarkers (4). The receptors are differentially 
expressed on healthy and diseased tissues (28,29,189,191), being senescent in healthy 
tissue. During anthrax infection or on cancer cells the receptors are expressed on the 
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surface of endothelial cells (189) and are readily accessible to an administered agent, thus 
there is a high potential for the agent to be actively internalised through receptor recycling 
(42,44,45). These aspects of the anthrax toxin receptors make them particularly interesting 
for the development of cancer targeting agents.   
 
As the anthrax toxin receptors interact with the ECM, it is important to assess their 
potential as a biomarker within a physiologically relevant tumour model. The HPV38E6E7-
FVB mouse model is genetically engineered to express human papillomavirus (HPV) type 
38 E6 and E7 oncoproteins, selectively expressed in the skin by a keratin promoter 
(170,171). In response to repeated UV irradiation the animals produce endogenous SCC, 
comparable to human pathology (170,171). Genetically engineered models are 
advantageous for the validation of targeted agents due to more accurate tumour 
physiology, development, location, microenvironment, and vascularisation (192,193).  
Whilst there are many options for developing an agent that targets the anthrax toxin 
receptors, one potential candidate is the exogenous ligand Protective Antigen (PA). PA is 
an 83 kDa protein produced by the bacterium B. anthracis that functions to target and 
translocate toxin molecules into cells through highly specific interactions with the anthrax 
toxin receptors (62). PA has been demonstrated to specifically target toxins to cancer cells 
in vitro (79) and inhibit tumour growth in various mouse models (80,81,194). Importantly, 
PA when administered alone is non-toxic. Recombinant PA produced in E. coli has been 
demonstrated to illicit no adverse immune responses in human clinical trials (94,95). There 
is currently limited information about PA biodistribution, clearance, and relative uptake in 
tumour tissues versus healthy tissues. The anthrax toxin receptors are known to be 
expressed on cells within the skin, lungs, and intestines (91,165). However, it is not known 
whether this expression will result in significant uptake of an intravenously administered 
agent. 
 
There are currently two studies that have assessed the blood clearance and biodistribution 
of PA. The blood clearance of intravenously administered PA in rodent models was 
determined using enzyme-linked immunosorbent assays (92). PA clearance was 
dependent on injected dose, resulting in a blood half-life of 10 minutes for a 20 µg dose 
and 53 minutes for 100 µg and 200 µg doses (92). Although PA demonstrated rapid blood 
clearance mice remained susceptible to anthrax toxin challenge up to 8 hours after 
injection, suggesting that PA remains at the surface of cells for a prolonged period (92). 
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The dose dependent blood clearance observed could be a result of receptor binding, 
suggesting that endogenous expression of the anthrax toxin receptors is a factor in 
clearance rate. Whilst these results demonstrate that an intravenously administered PA 
rapidly binds available anthrax toxin receptors, it was unable to answer whether the PA 
localises to specific tissues.  
 
Biodistribution of PA has been previously studied with 99mTc and 123I labelled PA 
intravenously injected into female BALB/c mice (195). The distribution of radiolabelled PA 
was visualised using scintigraphy 1 hour post injection and quantified by gamma counting 
24 hours post inject. Scintigraphy demonstrated 99mTc-PA localisation to the kidneys and 
bladder, proposed to be a result of rapid blood degradation and renal clearance, and 123I-
PA localisation to the liver and bladder (195). Biodistribution performed 24 hours post 
injection demonstrated primarily kidney radioactivity for both 99mTc and 123I labelled PA 
proteins (195). This study has several limitations that raise questions to the validity of their 
published results. Firstly, the 99mTc radiolabelling approach is described to follow a 
procedure using cysteine residues. As PA has no native cysteine residues and there is no 
mention of a modified PA protein, the described labelling method is not possible. With no 
data presented that validates radiolabelling, and significant differences between 99mTc-PA 
and 123I-PA localisation, it is questionable whether the observed results represent the 
distribution of PA. Secondly, as there is no anatomical reference to the 2D scintigraphy 
images and no quantitative organ uptake data at a comparable time point, it is difficult to 
discern the specific localisation of radioactivity with any confidence. Finally, the 
biodistribution performed 24 hours post injection has limited relevance based on the 
observed clearance at 1 hour post injection. It is probable that PA has been completely 
cleared from the animal by 24 hours post injection. As it is generally considered that 
proteins greater than 60 kDa are not cleared through the kidneys, further research is 
needed to validate observation of rapid kidney and bladder uptake. Additionally, 
identification of uptake in healthy skin tissue is needed, in order to determine if 
endogenous expression could affect targeting skin cancers.  
 
The rapid blood clearance and prolonged cell surface retention of PA could be 
advantageous as an imaging agent, allowing rapid identification of tumours that 
overexpress the anthrax toxin receptors with minimal background signal. In order to 
assess the potential of PA as a tumour targeting agent it is necessary to understand its 
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pharmacokinetic properties of absorption, distribution, metabolism, and excretion. 
Molecular imaging techniques are uniquely suited to assess the ability to target tumour 
biomarkers in a biologically relevant environment, providing non-invasive real time 
information and are likely to improve on the current knowledge of PA biodistribution and 
clearance. Positron Emission Tomography (PET) is a molecular imaging modality 
commonly used to assess the pharmacokinetic properties of compounds labelled with 
positron emitting radioisotopes, and can be used to identify and quantify their biological 
fate (196). Coupled with Computed Tomography (CT) as an anatomical reference, PET 
can be used to characterise the localisation of radio-labelled compounds within the 
subject.  
 
To assess the biodistribution and clearance of an intravenously administered PA, 
recombinant PA was labelled with an amine reactive desferrioxamine (DFO) chelator and 
89Zr. The 89Zr-DFO-PA protein demonstrated rapid blood clearance through hepatobiliary, 
renal, and immune mechanisms. The blood half-life of PA was approximately 35 minutes, 
resulting in the majority of radioactivity cleared from the blood by 24 hours post injection. 
Uptake in tumour associated skin was higher than healthy skin, but considerably lower 
than the uptake observed in clearance organs. The uptake and prolonged retention of 
radioactivity within the clearance organs is likely a result of intracellular accumulation of 
metabolised 89Zr. Overall there is potential to develop PA as a tumour targeting agent, but 
further research is needed to improve blood circulation and decrease uptake in clearance 
organs. 
 
4.2 Methods 
 
4.2.1 Protein conjugation 
 
p-SCN-Bn-Deferoxamine (DFO, 200 µg, Macrocyclics) was dissolved in 25 µL of dimethyl 
sulfoxide. PA (2 mg/mL, 1 mL) in 100 mM sodium bicarbonate buffer pH 9.2 was added to 
the DFO solution and incubated at 37 °C for 1 hour. The unreacted DFO was removed 
using a 10K MWCO Amicon Ultra-4 Centrifugal Filter (Merck).  
 
4.2.2 Radiolabelling 
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89Zr in 1 M oxalic acid (Perkin Elmer) was neutralised with 1M sodium bicarbonate buffer 
pH 9.2. 150 µL of DFO-PA (3 mg/mL) was mixed with 150 µL of 1 M HEPES buffer. 20 
MBq of neutralised 89Zr solution was added to the DFO-PA solution and incubated for 1 
hour at 37 °C with shaking. Free 89Zr was removed by buffer exchange into Phosphate 
Buffered Saline (PBS) using a PD MidiTrap G-25 column (GE life sciences).  
 
4.2.3 Radio TLC 
 
89Zr-DFO-PA (10 µL) was mixed with 50 mM diethylenetriaminepentaacetic acid (DTPA) in 
water (10 µL).  The protein/DTPA solution was spotted onto thin-layer chromatography 
(TLC) paper. The TLC was developed using 1:1 ethanol in water as eluent and allowed to 
air dry before imaging. The TLC was imaged using Bruker Carestream In Vivo MS FX Pro 
and Bruker Molecular Imaging Software. Percentage of radioactivity that remained static 
was determined by calculating the area under the peak in Bruker Molecular Imaging 
software. ImageJ was used for visualisation of radioactivity.  
 
4.2.4 Serum stability 
 
89Zr-DFO-PA (2mg/mL, 25 µL) was added to 500 µL of CD1 mouse serum and incubated 
at 37 °C with shaking. At 0, 1, and 3 hours after the addition of 89Zr-DFO-PA, 50 µL of 
serum solution was analysed by high performance liquid chromatography (HPLC) with a 
radioactivity detector. A 30 minute protocol was performed using a PL Aquagel-OH 8 µm 
particle size (Agilent) size exclusion column in water. Rate of degradation was determined 
based percentage of radioactivity with increased retention time using GraphPad Prism 
Software.   
 
4.2.5 Animal model 
 
Generation of the animal model was previously described in “3.2.5 Optical imaging”. 
Briefly, female HPV38E6E7-FVB mice received a single exposure of UVB radiation three 
times a week starting at 120 mJ/cm2, gradually increased to 450 mJ/cm2 by day 140. UV 
dosing remained at 450 mJ/cm2 until characteristic squamous cell carcinoma was 
observed (170). Female HPV38E6E7-FVB mice of similar age without UV irradiation were 
used as controls. 
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4.2.6 PET/CT acquisition 
 
HPV38E6E7-FVB mice were anaesthetised with 3-5 % isoflurane, monitored using pedal 
reflexes to ensure deep anaesthesia. A cannula was placed in the tail vein of each animal 
prior to being placed in an Inveon preclinical multimodality PET/CT scanner (Siemens). 
The concentration of anaesthesia was reduced to 1-3 % isoflurane and respiration was 
monitored throughout the imaging experiments using a BioVet animal monitoring system 
(Polarean). The mice were injected with 89Zr-DFO-PA (~1.5 MBq, 150 µL) in phosphate 
buffered saline (PBS) via the tail vein cannula, followed by 50 µL of PBS. PET/CT data 
was acquired and reconstructed using Inveon Acquisition Workplace (Siemens). Dynamic 
PET data was acquired over 90 minutes, with the list mode data sorted into 39 frames (10 
x 30 second, 15 x 60 second, 14 x 300 second time frames). The PET sinograms were 
reconstructed using filtered back-projection (FBP) and ordered-subset expectation 
maximization (OSEM2D). CT images were acquired immediately after PET acquisition 
using an X-ray source (80 kV and 500 µA). CT images were acquired over 12 minutes 
using 360° rotation (3° rotation steps), with low magnification and 2 x 2 bins, and 
reconstructed using Feldkamp reconstruction software (Siemens). Static PET data was 
acquired over 45 minutes. Image reconstruction and CT imaging for static PET scans was 
performed as previously described. 
 
4.2.7 PET/CT image analysis 
 
PET/CT image analysis was performed with Inveon Research Workstation software 
(Siemens). PET and CT datasets were aligned to ensure accurate overlap. Three 
dimensional regions of interest determined for the heart, lungs, liver, kidneys, bladder, 
brain, and tumour for each animal using CT information to delineate organs. Activity was 
expressed as percentage of decay-corrected injected activity per cm3, approximated as 
percentage injected dose per gram (%ID/g).  
 
4.2.8 Biodistribution studies 
 
Animals were anaesthetised with 3-5 % isoflurane and injected with 89Zr-DFO-PA in PBS 
(~1.5 MBq) via tail vein. After injection the animals were housed individually and allowed to 
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recover. At each biodistribution time point the animals were anaesthetised, a sample of 
blood was removed by cardiac puncture and the animal was immediately euthanised by 
cervical dislocation. Organs and tissue samples were harvested, spotted to remove excess 
blood, and weighed. Radioactivity in tissue was counted using a PerkinElmer 2480 
Automatic Gamma Counter. The injected dose was calculated as the radioactivity removed 
from the injection syringe, determined with a dose calibrator (Capintech CRC-25PET), 
corrected for residual radioactivity remaining within the tail. 
 
4.3 Results 
 
4.3.1 Confirmation of PA radiolabelling and stability 
 
Radio Thin Layer Chromatography (radio-TLC) was performed to determine the degree of 
PA radiolabelling, resulting in 85.8 % of the radioactivity associated with PA (Fig. 4-1A). 
The 89Zr-DFO-PA was isolated from unchelated 89Zr by buffer exchange into PBS and 
reanalysed by radio-TLC, resulting in 100 % of radioactivity associated with the protein 
(Fig. 4-1B) and a specific activity of ~35 MBq/mg. To ensure the PA protein does not 
undergo radiolysis radio-TLC was performed 0, 24, and 48 hours after radiolabelling (Fig. 
4-2). The radioactivity remained associated with PA at each time point demonstrated by 0 
% radioactivity migrating on the radio-TLC.  
Figure 4-1. Confirmation of radioactivity associated with PA. 
10 µl of 89Zr-DFO-PA/DTPA solution was spotted onto a TLC plate and developed using a 
solution of equal parts ethanol and water. The radiolabelling reaction resulted in 85.8 % of 
radioactivity remaining static and thus associated with PA (A). The 89Zr-DFO-PA was 
buffer exchanged into PBS to remove free 89Zr for injection into animals, and radio-TLC 
repeated (B). 100 % of radioactivity present within the 89Zr-DFO-PA sample injected into 
animals was associated with PA. 
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Serum stability of 89Zr-DFO-PA was assessed by incubating the radiolabelled protein in 
CD1 mouse serum. The 89Zr-DFO-PA serum sample was incubated at 37 °C with shaking 
and a sample analysed by radio-high-performance liquid chromatography (radio-HPLC) at 
0, 1, and 3 hours. The radio-HPLC chromatogram was used to determine the percentage 
of radioactivity associated with the intact PA protein versus degraded components, 
resulting in approximately 10% degradation per hour.   
 
4.3.2 In vivo PET/CT demonstrates rapid uptake and clearance of 89Zr-DFO-PA 
 
Dynamic uptake of 89Zr-DFO-PA in HPV38E6E7-FVB SCC tumour bearing mice (UV+) was 
monitored for 90 minutes using PET/CT (Fig. 4-3). After the initial injection via tail vein the 
radioactivity within the heart and lungs peaked at 26.88 ± 2.82 % ID/g and 13.12 ± 4.46 % 
ID/g respectively, slowly decreasing over time (Fig. 4-3A). Radioactivity within the liver 
increased rapidly to 10.66 ± 1.99 % ID/g 5 minutes after injection before slowly increasing 
to 12.45 ± 1.38 % ID/g (Fig. 4-3B). Liver uptake continued to increase over time reaching 
18.2 ± 2.26 % ID/g 5 hours post injection. The kidneys demonstrated a logarithmic 
increase over the course of the dynamic PET scan reaching 17.36 ± 1.31 % ID/g 90 
minutes post injection and continuing to increase to 28.95 ± 1.90 % ID/g 5 hours post 
injection. Low radioactivity was present within the brain peaking at 2.42 ± 0.35 % ID/g, 
which slowly decreased over time. The bladder radioactivity remained fairly constant 
during the dynamic scan at ~1 % ID/g, but was increased to 6.8 ± 1.26 % ID/g 5 hours post 
injection.  The tumour region demonstrated rapid uptake after injection, however showed 
Figure 4-2. 89Zr-DFO-PA remains stable in PBS. 
The 89Zr-DFO-PA protein was buffer exchanged into PBS for injection into animals and 
analysed by radio-TLC 0, 24 and 48 hours thereafter. 100 % of radioactivity remained 
associated with PA at all time points. 
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greater variability than the other organs. The heterogeneity of tumour development and the 
resolution of the PET may be factors in the variability observed in the tumour uptake.  
 
To visualise the distribution of 89Zr-DFO-PA, PET/CT imaging was performed on SCC 
tumour bearing mice 5, 24, and 48 hours post injection (Fig. 4-4). At 5 hours post injection 
the radioactivity was primarily observed within the kidneys, liver, and GI tract, with lower 
but detectable radioactivity present in the tumour regions on the dorsal skin and ears. High 
radioactivity remains in the kidneys 24 hours post injection, while the liver slightly 
Figure 4-3. Dynamic uptake of 89Zr-DFO-PA into HPV38E6E7-FVB SCC tumour 
bearing mice. 
HPV38E6E7-FVB SCC tumour bearing (UV+) mice were administered ~1.5 MBq of 89Zr-
DFO-PA intravenously. Uptake of radioactivity was monitored for 90 minutes. Dynamic 
PET data (lines) represents mean % ID/g (n=3) within the region of interest for each organ 
or tissue. Static PET was performed 5 hours post injection. Static PET data (circles) 
represents mean % ID/g (n=5), with standard deviation of the mean as error bars. 
Volumetric ROIs were determined using the anatomical CT image and transferred to the 
PET data. Decay corrected % ID/g was determined individually for each animal based on 
calculated injected dose using Siemens Inveon Research Workplace software. 
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decreased. Radioactivity remains in the tumour region, but the previously observed 
radioactivity in the GI tract is almost undetectable. After 48 hours the radioactivity in the 
kidneys still remains high, while the liver has further decreased. The radioactivity in the 
tumour region has further decreased but remains detectable. The PET images 
demonstrate the majority of radioactivity retained within the kidneys is localised to the 
cortex, the region responsible for filtering and reabsorption of blood components (Fig. 4-5).  
 
4.3.3 Intravenous administration of 89Zr-DFO-PA results in radioactivity retained primarily 
within clearance organs 
 
Ex vivo biodistribution was performed on selected tissues and organs at 24 and 48 hours 
post injection for SCC tumour bearing animals (Fig. 4-6A) and 3, 24, 48 and 168 hours 
post injection for control animals (Fig. 4-6B). Radioactivity per gram of tissue was 
measured using gamma counting, and expressed as a decay corrected % ID/g (Table 4-
1). The biodistribution of 89Zr-DFO-PA resulted in peak radioactivity detected 3 hours post 
injection in in the majority of organs, corresponding with low blood radioactivity. In the UV– 
control animals the highest uptake was observed in the kidneys (102.63 ± 8.67 % ID/g). 
The liver (20.52 ± 5.33 % ID/g) and spleen (15.86 ± 1.92 % ID/g) resulted in the second 
and third highest uptake followed by the lungs (8.44 ± 1.92 % ID/g) and GI tract (5.63 ± 
0.35 % ID/g). Relatively low radioactivity was observed in the bone (2.18 ± 0.45 % ID/g), 
muscle (0.29 ± 0.06 % ID/g), and skin (0.57 ± 0.23 % ID/g) that remained fairly constant at 
all biodistribution time points.  
 
Tumour biodistribution results were highly variable, potential a result of the model 
heterogeneity with respect to tumour development. Due to difficultly delineating tumour 
from surrounding non-tumour tissue by sight the tumour specific injected dose per gram is 
likely to be under reported. The biodistribution of 89Zr-DFO-PA in tumour and control 
animals was generally similar at 24 and 48 hours post injection. The kidney uptake was 
discernibly different 24 hours post injection, where the tumour animals resulted in lower 
kidney radioactivity, but returned to comparable levels 48 hours post injection. Comparison 
of ratio of radioactivity in tumour to reference tissues at each biodistribution time point 
(Table 4-2) resulted in increasing tumour to blood and tumour to muscle ratios with time, 
while the tumour to skin radioactivity remained fairly constant.  
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Table 4-1. Ex vivo biodistribution of 89Zr-DFO-PA in HPV38E6E7-FVB mice. 
 Control (UV−) Tumour (UV+) 
 3h 
(n=3) 
1d 
(n=3) 
2d 
(n=3) 
7d 
(n=1) 
1d 
(n=2) 
2d 
(n=3) 
Blood 3.38 ± 0.10 
0.76 ± 
0.03 
0.16 ± 
0.06 0.06 
0.37 ± 
0.08 
0.14 ± 
0.02 
Heart 2.65 ± 0.22 
1.78 ± 
0.03 
1.77 ± 
0.51 1.48 
2.33 ± 
0.16 
1.93 ± 
0.33 
Lungs 8.44 ± 1.92 
5.14 ± 
0.86 
4.79 ± 
1.11 3.34 
3.28 ± 
0.72 
2.78 ± 
0.65 
Liver 20.52 ± 5.33 
16.36 ± 
2.28 
15.78 ± 
3.97 12.57 
24.18 ± 
4.82 
18.43 ± 
0.79 
Spleen 15.86 ± 1.92 
12.337 ± 
3.47 
10.57 ± 
1.69 9.21 
12.85 ± 
0.10 
10.18 ± 
1.92 
Kidneys 102.63 ± 8.67 
89.30 ± 
23.21 
79.14 ± 
13.28 62.92 
67.50 ± 
4.74 
74.03 ± 
16.51 
GI tract 5.63 ± 0.35 
1.50 ± 
0.45 
0.82 ± 
0.09 0.50 
2.11 ± 
0.26 
0.82 ± 
0.10 
Muscle 0.29 ± 0.06 
0.24 ± 
0.05 
0.19 ± 
0.03 0.18 
0.23 ± 
0.02 
0.27 ± 
0.01 
Bone 2.18 ± 0.45 
2.32 ± 
0.06 
2.12 ± 
0.56 2.26 
1.76 ± 
0.03 
1.58 ± 
0.42 
Brain 0.15 ± 0.01 
0.05 ± 
0.01 
0.04 ± 
0.01 0.06 
0.06 ± 
0.01 
0.05 ± 
0.01 
Skin 0.57 ± 0.23 
0.67 ± 
0.14 
0.47 ± 
0.18 0.29 
0.68 ± 
0.73 
0.73 ± 
0.21 
Tumour (dorsal) n/a n/a n/a n/a 1.00 ± 0.79 
1.67 ± 
0.27 
Tumour (ear) n/a n/a n/a n/a 3.17 ± 1.77 
1.91 ± 
0.37 
Values represent mean decay corrected percentage injected dose per gram of tissue 
(% ID/g) ± the standard deviation of the mean. Muscle samples were taken from the 
hind limb; bone samples contain the femur, tibia, and fibula; skin samples were taken 
from upper dorsal region.  
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4.4 Discussion 
 
Despite relatively low radioactivity, tumour uptake was observed throughout the imaging 
experiments suggesting that radioactivity is highly localised within the tumour. As a result 
of high radioactivity uptake and retention in clearance organs, visualisation of some 
tumours is limited. Autoradiography, which has higher spatial resolution than PET imaging 
(197,198), could be used to better visualise the localisation of radioactivity within the 
tumour region and improve the accuracy of the biodistribution results.  
 
The anthrax toxin receptors have been described as highly expressed in the skin, 
intestines, and lungs (91,165). Biodstribution of 89Zr-DFO-PA demonstrated low 
radioactivity in the skin, which could not be visualised in the PET images. Whilst 
radioactivity was present in the GI tract within the first few hours after injection, it had 
discernibly decreased by 24 hours, suggesting the radioactivity is not the result of PA 
uptake. Based on these results, the expression of the anthrax toxin receptors within the 
skin and GI tract is not likely to impact tumour visualisation. Uptake of radioactivity was 
observed in the lungs and is likely due to anthrax toxin receptor expression, whether this is 
due to one receptor in particular is not known.  
 
Biodistribution and PET imaging demonstrated that the majority of 89Zr-DFO-PA is cleared 
from the blood by hepatobiliary, renal, and immune mechanisms within 3 hours and 
excreted by 24 hours. The radioactivity that remained after 24 hours is likely a result of 
intracellular retention of the catabolised 89Zr products. These results suggest a blood 
circulation half-life of approximately 35 minutes, similar to results described in the literature 
(92), but dissimilar to previous results with fluorescent dye conjugated PA where 
circulation was still observed 8 hours post injection. 
Table 4-2. 89Zr-DFO-PA tumour-to-reference tissue ratio 
 1 day p.i. 2 day p.i. 
Tumour : Blood 2.51 ± 1.11 11.88 ± 1.59 
Tumour : Muscle 4.49 ± 2.68 6.18 ± 0.89 
Tumour : Skin 2.07 ± 0.79 2.47 ± 0.75 
p.i. post injection. Ratios were determined individually for each animal, values represent 
mean ratio ± standard deviation of the mean. 
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Figure 4-4. Visualization of 89Zr-DFO-PA distribution within SCC tumour bearing 
mice. 
Representative sagittal slices from static PET images of a SCC tumour bearing (UV+) 
HPV38E6E7-FVB mouse performed 5, 24, and 48 hours post intravenous injection of ~1.5 
MBq 89Zr-DFO-PA (A). L, liver; K, Kidney; I, intestine. Calibration bar represents % ID/g. 
3D rendering of a mouse possessing an ear tumour 24 hours post injection of 89Zr-DFO-
PA (B) and dorsal tumour 48 hours post injection (C). 3D renderings were created using 
Siemens Inveon Research Workplace software. White arrows indicate tumours. 
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Non-specific amine bioconjugation may result in significant variability in distribution and 
clearance of PA due to the hydrophobicity and electrostatic properties of the conjugate, 
which could account for different blood clearance times. The observed differences 
between the 89Zr-DFO-PA and PA-Cy5 compounds could be the result of surface charge 
differences. The 89Zr-DFO molecule is positively charge at physiological pH, while the Cy5 
molecule is negatively charged. It has been previously reported that increasing the surface 
charge results in increased macrophage uptake and likely increased clearance (157). To 
reduce the impact of the conjugate on PA a different method of bioconjugation would be 
needed. One method of site specific bioconjugation could be achieved by the incorporation 
of a cysteine residue, as PA does not natively contain cysteine residues. However, with 
Figure 4-5. PET/CT images demonstrate localization of radioactivity to the kidney 
cortex. 
Representative PET/CT axial, coronal, and sagittal images 48 hours post injection of 89Zr-
DFO-PA. Radioactivity is localized to the outer portion of the kidney demonstrating 
retention within the cortex. Crosshairs demonstrate 3D focal point as the centre of the right 
kidney. Calibration bar represents % ID/g. 
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further characterisation and development, a highly decorated PA protein that clears quickly 
may be an advantageous agent for imaging purposes.  
 
The clearance of the intravenously administered 89Zr-DFO-PA occurs through 
hepatobiliary, renal, and immune clearance mechanisms. Hepatic clearance of 89Zr-DFO-
PA is evidenced by radioactivity within the GI tract, as hepatic clearance is the only 
Figure 4-6. Ex vivo biodistribution of 89Zr-DFO-PA in HPV38E6E7-FVB mice. 
Biodistribution was performed on SCC tumour bearing (UV+) mice 24 and 48 hours post 
injection (A), and control (UV−) mice 3, 24, 48, and 168 hours post injection (B). Muscle 
samples were taken from the hind limb; bone samples contain the femur, tibia, and fibula; 
skin samples were taken from upper dorsal region. Bars represent mean decay corrected 
% ID/g with standard deviation of mean as error bars. 
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mechanism for an intravenous administered compound to partition into the GI tract. 
Maximum radioactivity was observed in the GI tract 3 hours post injection but dropped 
considerably by 24 hours post injection, this suggests that 89Zr-DFO-PA is metabolised in 
the liver within the first few hours of injection and radioactive metabolites are excreted via 
the biliary system into the GI tract for faecal excretion. Since radioactivity remains within 
the liver after clearance through the GI tract, it is likely that what remains is unable to be 
excreted.  
 
Kidney clearance was observed in the dynamic PET uptake experiment, where 
radioactivity increases over the 90 minute experiment, suggesting that there is immediate 
clearance of 89Zr-DFO-PA. Within the kidney, blood enters the filtration units known as 
nephrons that consist of a knot of fenestrated capillaries called a glomerulus. The 
glomerulus has pores of approximately 70–100 nm in diameter that allow components of 
the blood to diffuse through (199). Surrounding the glomerulus is a negatively charged 
glomerular basement membrane (200) and cells known as podocytes (201) that function to 
inhibit diffusion of large blood components. Gaps or filtration slits between the podocytes, 
which are on average 12 nm (202), further limit molecules that can pass. Due to these 
aspects of kidney filtration it is generally regarded that proteins larger than 60 kDa are 
unable to pass through the kidney and will instead remain within circulating blood. 
However, hydrodynamic radius and protein charge will have a greater effect on kidney 
excretion than absolute molecular weight (203). Although PA is 83 kDa, its elongated 10 x 
5 x 3 nm structure (63) may allow some degree of diffusion through the glomerulus and 
could explain the immediate uptake observed in the dynamic PET experiment. Although 
there was evidence of 89Zr-DFO-PA clearance based on kidney uptake during the dynamic 
PET scan, radioactivity was not detected in the bladder until 5 hours post injection. As the 
proximal convoluted tubule reabsorbs 99% of amino acids (204) it is likely that 89Zr-DFO-
PA or metabolised radiolabelled fragments thereof are initially reabsorbed, limiting any 
radioactivity reaching the bladder. Eventually the 89Zr-DFO-PA is metabolised into 89Zr-
DFO-lysine, which if present in the blood will be excreted via the urine and not reabsorbed 
by the convoluted proximal tubule (205).    
 
The uptake of radioactivity within the spleen demonstrates potential immune clearance 
(206). As PA is a foreign protein there is potential for it to be removed by macrophages 
within the spleen. Although clinical trials have demonstrated that recombinant PA does not 
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illicit adverse immune responses in humans (95), the immune clearance of PA is unknown. 
However, as the spleen structure and immune system of mice and humans is significantly 
different (207,208), the immune clearance observed may not be relevant.  
 
89Zr has been demonstrated to possess prolonged intracellular retention that has been 
utilised to improve tumour contrast of antibodies with long blood circulation (209) and in 
vivo cell tracking studies (210-212). Compounds that exhibit rapid renal clearance, such as 
antibody fragments, result in very high kidney uptake and retention (213). The prolonged 
retention of radioactivity observed in the clearance organs after administration of 89Zr-
DFO-PA is probably due to intracellular catabolism into 89Zr-DFO-lysine, a molecule that is 
unable to be incorporated into proteins by the cell or transported into the blood for 
clearance (205). The most prominent uptake of radioactivity was observed within the 
cortex of the kidneys, the region that is responsible for filtration and reabsorption of blood 
components. When radiolabelled proteins or peptides are reabsorbed by the convoluted 
proximal tubule endothelial cells the catabolised 89Zr-DFO-lysine remains within the cells 
increasing radioactivity over time. A similar process is likely to occur in endothelial cells, 
hepatocytes, and macrophages of the liver and spleen.  
 
It is important to note that these results are the distribution of radioactivity, and it is not 
possible to discern whether the observed distribution is due to anthrax toxin receptor 
interactions or non-specific uptake. Based on previous data with intravenously 
administered fluorescent PA, where limited clearance organ uptake was observed, we 
hypothesise that the majority of radioactivity in the clearance organs is due to intracellular 
retention of 89Zr. To confirm our hypothesis, high resolution autoradiography and histology 
could be used to identify the localisation of radioactivity within different organs and 
correlate uptake to anthrax toxin receptor expression. Although these biodistribution 
results are considerably different than those published in the literature (195), we observe 
similar blood clearance to published literature (92) and clearance mechanisms consistent 
with a protein the size of PA. As it is expected that a 99mTc and 89Zr labelled protein would 
behave similarly, particularly with respect to kidney uptake in the proximal tubule and 
prolonged cellular retention, it is unlikely that the published 99mTc-PA data is accurate. 
Based on these results 89Zr-DFO-PA is not a suitable imaging agent due to limited tumour 
uptake and non-specific retention of radioactivity, but there is potential for improvement.  
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Whilst the rapid blood clearance observed can be advantageous for earlier imaging after 
injection, it requires highly specific and rapid tumour uptake. To improve the imaging 
results of this study there are a number of potential avenues to limit the uptake in the 
clearance organs. Using a radionuclide with lower intracellular retention or a cleavable 
conjugate would likely reduce renal uptake of the radioactivity. Alternatively, PA could be 
modified to increase its blood circulation time in an effort to increase tumour uptake and 
reduce blood clearance (214). Increased blood circulation is also advantageous for 
potential therapeutic development of PA. Overall, PA has potential as a diagnostic or 
therapeutic agent targeting the tumour specific overexpression of anthrax toxin receptors, 
but more work is needed to improve the in vivo characteristics of PA to maximise tumour 
uptake and minimise non-specific retention. 
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Chapter 5 – Conclusions and Future Directions 
 
5.1 Conclusions 
 
B. anthracis Protective Antigen (PA) has the potential to be developed as a systemically 
administered targeted molecular imaging agent for cutaneous squamous cell carcinoma 
(SCC). We have shown that recombinant PA can be efficiently and reproducibly produced 
using an E. coli expression system and isolated using liquid chromatography purification 
techniques. This allows for relative inexpensive and straight forward production of PA for 
research purposes. Recombinant PA can be modified with the near infra-red fluorescent 
dye sulfo-Cyanine5 (PA-Cy5) and 89Zr radionuclide chelate desferrioxamine (89Zr-DFO-
PA) with non-specific amine reactive bioconjugation techniques. The amine modified PA 
maintains receptor specific binding and cell internalization, determined in vitro using PA-
Cy5.  
 
The intravenously administered PA-Cy5 was highly specific for endogenous mouse SCC 
tumours. PA-Cy5 demonstrated rapid tumour uptake and clearance, which resulted in 
exclusive tumour detection 24 hours post injection and retention of tumour fluorescence 
beyond 48 hours post injection. The tumour specific uptake of PA-Cy5 can be attributed to 
the overexpression of anthrax toxin receptors. We have for the first time identified that both 
anthrax toxin receptors, Tumour Endothelial Marker 8 (TEM8) and Capillary 
Morphogenesis Gene 2 (CMG2), are overexpressed on the mouse cutaneous SCC 
tumours relative to normal healthy skin tissue. In addition, we are the first to co-stain for 
the highly conserved receptors, identifying the localisation of TEM8 and CMG2 within SCC 
tumours. The anthrax toxin receptors are generally localised to different structures within 
cutaneous SCC, with TEM8 localised to the dermis and CMG2 to the epidermis. Despite 
the overexpression of both receptors, the intravenously injected PA-Cy5 was more 
significantly colocalised with TEM8. As TEM8 is more widely expressed in the vascularised 
dermal region, compared to CMG2 expression in the non-vascularised epidermal region, 
the colocalisation of PA-Cy5 to TEM8 may be a result of greater accessibility to an 
intravenously administered agent.  
 
Further studies performed with a PA radiotracer, 89Zr-DFO-PA, demonstrated low but 
detectable tumour uptake. The 89Zr-DFO-PA was rapidly cleared through hepatobiliary, 
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renal, and immune mechanisms based on the uptake observed within the kidneys, the 
liver, and the spleen. We are the first to observe renal clearance of PA using dynamic PET 
imaging, despite PA being larger than the generally accepted molecular weight cut off for 
glomerular filtration. This renal clearance may be a significant factor in the rapid blood 
clearance of PA. As a result of the rapid blood clearance and subsequent metabolism, the 
89Zr-DFO-PA results in significant non-specific uptake that was retained within cells for 
long periods, particularly in organs associated with clearance. Based on this data 89Zr-
DFO-PA is not a suitable imaging agent. Assessment of other radionuclides that do not 
exhibit the same degree of cellular retention may improve results, however additional 
modifications may be required to prolong the blood circulation of PA.  
 
It is likely that the imaging molecule and method of bioconjugation will have a significant 
effect on PA biodistribution characteristics. Although both the Cy5 and 89Zr-DFO molecules 
are cell impermeable, PA exhibited different in vivo distribution and clearance 
characteristics with the negatively charged dye compared to the positively charge 89Zr-
DFO. This result suggests that non-specific amine modification with negatively charged 
imaging molecules would improve in vivo tumour targeting characteristics, but further 
research is needed using more comparable molecules to identify the effect of different 
charges on distribution and tumour uptake. 
 
Overall this work demonstrates that the anthrax toxin receptors are potential cancer 
biomarkers of cutaneous SCC, with tumour specific upregulation demonstrated on a 
physiologically relevant HPV positive UV induced mouse model. In addition to selective 
overexpression of tumours, the anthrax toxin receptors are particularly interesting targets 
that may link pathological changes within the extracellular matrix (ECM) to tumour 
progression and development. Importantly, the anthrax toxin receptors do not appear to be 
essential in normal healthy adult processes thus targeting them may have limited side 
effects. PA is highly specific to the overexpression of anthrax toxin receptors and has the 
potential to be developed as a systemically administered diagnostic or therapeutic agent, 
utilising bioconjugation of imaging agents or drugs, for translational research of cutaneous 
SCC and other cancers. 
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5.2 Future Directions 
 
5.2.1 Anthrax toxin receptors as cancer biomarkers 
 
To determine the potential of the anthrax toxin receptors as cancer biomarkers, further 
characterisation of their relative expression in vivo on healthy and tumour tissue is needed. 
Overexpression of is often assessed using mRNA or protein expression within cell or 
tissue lysates. The disadvantage of these techniques is that they are unable to delineate 
cell surface protein from intracellular protein. From the perspective of molecular targeting, 
the relative expression at the cell surface of healthy and diseased tissue is of significant 
importance.  
 
In vitro cell studies are commonly used to identify cell surface expression of proteins 
isolated populations of cells, however the biological microenvironment has been 
demonstrated to significantly affect the expression of the anthrax toxins receptors 
(21,39,43). As the anthrax toxin receptors are principally involved in interactions with ECM 
(32,33,35,41,43,98,99) greater weight needs to be placed on in vivo characterisation of 
expression to appropriately assess their potential as cancer biomarkers. 
 
With clinical translation in mind, the expression of the anthrax toxin receptors could be 
determined on clinical SCC samples using immunofluorescence or immunohistochemistry 
techniques. Identifying qualitative overexpression in clinical samples is of significant 
importance to characterise the anthrax toxin receptors as biomarkers of SCC. As the 
clinical practice of skin cancer excision requires a margin of several millimetres to be 
removed around the cancer (215), there is potential to identify whether the anthrax toxin 
receptors are able to appropriately delineate tumour tissue from healthy tissue. 
 
Further work is also needed to characterise the anthrax toxin receptors as cancer 
biomarkers using physiologically relevant preclinical models. It is not currently known what 
cells within a heterogeneous tumour overexpress the anthrax toxin receptors, nor the 
effect of their upregulation in vivo. Tumour growth studies using TEM8 knockout mice (34) 
and TEM8 knockdown xenografts (40,41) suggest that the expression of TEM8 is required 
in healthy tissue and cancer cells for optimal tumour development. Using the HPV38E6E7-
FVB mouse model, the heterogeneous SCC tumours could be digested and analysed by 
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fluorescence activated cell sorting to identify and characterise the cell populations that 
overexpress the anthrax toxin receptors. Determining whether the expression of anthrax 
toxin receptors occurs on cancer cells or whether cancer signalling causes upregulation of 
expression on the surrounding healthy cells is important for the development of a targeted 
agent.  
 
The HPV38E6E7-FVB mouse model would be uniquely suited for the longitudinal 
assessment of anthrax toxin expression as cutaneous SCC develops. This model would 
allow for characterising anthrax toxin receptor expression throughout SCC development 
and may identify the point at which the anthrax toxin receptors become upregulated. 
Additionally, this model could be used for in vivo gene silencing of the anthrax toxin 
receptors using topical administration of siRNAs (216) during tumour development. 
Targeted knockdown before and after tumour onset may identify the effect of anthrax toxin 
receptor upregulation on tumour physiology and development.  
 
5.2.2 Development and characterisation of PA as a targeted agent 
 
PA has several positive attributes that make it attractive for development as a targeted 
agent. PA is highly specific for the conserved anthrax toxin receptors (61,104), can be 
produced in high yields using bacterial fermentation (116), and causes no adverse immune 
reactions in humans (94,95). Additionally, PA has the ability to oligomerise at the cell 
surface (138) and actively initiate internalisation (44,45), facilitating its own uptake into 
cells relative to the expression of the anthrax toxin receptors. As the expression of these 
receptors is upregulated in many cancers relative to generally low expression in healthy 
tissues, it is expected that the tumour uptake of PA would be significantly higher than 
healthy tissue.  
 
PA has potential as a systemically delivered diagnostic agent for cutaneous SCC, but 
requires further research to determine if it can provide greater cancer detection or 
delineation than current clinical methods. Using the HPV38E6E7-FVB model, the PA-Cy5 
agent could be administered at earlier time points during UV irradiation to determine the 
earliest point in tumour development that PA is able to delineate SCC tumours. 
Immunohistochemistry and immunofluorescence techniques can be used to validate the 
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association of fluorescence localisation with tumour development and anthrax toxin 
receptor expression.  
 
As we observed significant differences in the biodistribution of PA-Cy5 and 89Zr-DFO-PA, 
further work is needed to understand how the addition of different imaging agents may 
affect the tumour uptake and biodistribution of PA. Systematic analysis of different dye 
molecules that vary in structure, membrane affinity, and charge can provide information on 
how changes to the protein surface effect in vivo characteristics such as blood circulation, 
localisation, and clearance. Similar analysis can also be performed with respect to 
radionuclide chelators for 64Cu and 68Ga, to develop an optimal PET imaging agent. In 
addition to the effect of the imaging molecule, analysis of non-specific amine modification 
and site specific cysteine modification would also provide valuable information. Although it 
is generally detrimental to significantly label antibodies (156), we have shown that the 
highly decorated PA-Cy5 is selective for cutaneous SCC tumours. The ability to 
significantly modify the surface of PA may prove to be an advantageous attribute.  
 
Finally, the question remains as to whether the wild type PA molecule is the best option for 
targeting the overexpression of anthrax toxin receptors on tumours. There are multiple 
modified PA proteins described in the literature that may possess better in vivo 
characteristics. These include a protease resistant mutant (116), an isolated domain IV 
that can be independently produced and maintains receptor interaction (217), or a binding 
loop peptide (90). An alternative approach to developing a tumour targeting agent that 
utilizes the interaction between PA and the anthrax toxin receptors is peptide grafting 
(218). Inhibitor cysteine knot peptides are extremely diverse in nature and demonstrate 
high chemical, thermal, and proteolytic stability (218). Grafting the region of PA that binds 
directly to the metal ion dependant adhesion site of the anthrax toxin receptors to an 
inhibitor cysteine knot peptide could produce a selective and stable peptide for targeting 
tumours. Peptide grafting is a relatively new approach to developing novel targeted agents 
and is a promising method for future research.  
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